

LIST OF PUBLICATIONS

Robert Henry (Haim Pinhas) Belmaker

PUBLICATIONS

Books and Special Journal Issues Edited

1. Gershon E, Belmaker RH, Kety S and Rosenbaum M (ed.) The Impact of Biology on Modern Psychiatry, Plenum Press, New York, 1977.
2. Belmaker RH and Van Praag HM (eds.) Mania, An Evolving Concept, Spectrum Publications, New York, 1980.
3. Bannet J and Belmaker RH (eds.) New Directions in Tardive Dyskinesia Research, Karger, Basel, 1983.
4. Lerer B, Weiner R and Belmaker RH (eds.) ECT: Basic Mechanisms, John Libbey, London, 1984.
5. Zohar J and Belmaker RH (eds). Treating Resistant Depression, Spectrum Press, New York, 1987.
6. Dahlstrom A Belmaker RH and Sandler M (eds). Progress in Catecholamine Research: Part A: Basic Aspects & Peripheral Mechanisms, Alan R. Liss, Inc., 1989.
7. Sandler M, Dahlstrom A and Belmaker RH (eds). Progress in Catecholamine Research: Part B: Central Aspects, Alan R. Liss, Inc., 1989.
8. Belmaker RH, Sandler M and Dahlstrom A (eds). Progress in Catecholamine Research: Part C: Clinical Aspects, Alan R. Liss, Inc., 1989.
9. Bergener M, Belmaker RH and Tropper M (eds). Psychopharmacotherapy in Old Age. Springer, New York, 1993.
10. Manji HK, Bowden CL, Belmaker RH (eds). Bipolar Medications: Mechanisms of Action. APA Press, Washington DC, 2000.
11. George MS, Belmaker RH (eds). Transcranial Magnetic Stimulation (TMS) in Neuropsychiatry. APA Press, Washington DC, 2000.
12. Benjamin J, Ebstein R, Belmaker RH (eds). Molecular Genetics and Human Personality. APA Press, Washington DC, 2002.

13. Agam G, Belmaker RH, Everall I (eds). *The Post-Mortem Brain in Psychiatric Research*. Kluwer Academic Publishers, Norwell, MA. 2002.
14. Belmaker RH, Bersudsky Y (eds). *Progress in Neuro-Psychopharmacology & Biological Psychiatry, Special Issue: Mechanism of Atypicality of Antipsychotic Drugs*. *Progress in Neuro-Psychopharmacology and Biological Psychiatry*, 27 (7):1067-1069: 2003.
15. Belmaker RH, Bersudsky Y (eds). *Special Issue: Mechanism of Atypicality of Antipsychotic Drugs*. *Progress in Neuro-Psychopharmacology & Biological Psychiatry*, Elsevier, 27(7):2003.
16. Belmaker RH, Agam Galila (eds). *Special Issue: Lithium and Mood Stabilizers: Mechanisms of Action*. *Clinical Neuroscience Research*. (4):2004.
17. Levine J, Belmaker RH (eds). *Special Issue: Homocysteine in Psychiatry: State of the Art*. *Progress in Neuro-Psychopharmacology & Biological Psychiatry*, Elsevier 29(7):2005.
18. George MS, Belmaker RH (eds). *Transcranial Magnetic Stimulation in Clinical Psychiatry*. APPI Press, Washington DC, 2007.
19. Belmaker RH, Arbelle S (eds). *Special Issue (part 1 and part II): Pediatric Bipolar Disorder*, *Israel Journal of Psychiatry*, 2012.

Chapters in Books and Unrefereed Articles

1. Lamprecht F, Wyatt RJ, Belmaker RH, Cohen S and Pollin W (1973). Plasma dopamine-beta-hydroxylase in identical twins discordant for schizophrenia. In: "New Frontiers in Catecholamine Research", Snyder S and Usdin E (eds) Pergamon Press, New York, pp 1123-1126.
2. Wyatt RJ, Belmaker RH and Murphy DL (1975). Low platelet monoamine oxidase and vulnerability to schizophrenia. In: "Genetics and Psychopharmacology", Mendlewicz J (ed) Karger, Basel, pp 38-56.
3. Belmaker RH and Ebstein RP (1977). The search for genetic polymorphisms of human biogenic amine-related enzymes. In: "The Impact of Biology on Modern Psychiatry", Gershon E, Belmaker RH, Rosenbaum M and Kety SS (eds) Plenum Press, New York, pp 241-260.
4. Ebstein RP and Belmaker RH (1977). A comparison of the effect of lithium and haloperidol on human peripheral beta- adrenergic adenylate cyclase. In: "The Impact of Biology on Modern Psychiatry", Gershon E, Belmaker RH, Rosenbaum M and Kety SS (eds) Plenum Press, New York, pp 27-40.
5. Ebstein RP and Belmaker RH (1979). Lithium and brain adenylate cyclase. In: "Lithium Controversies and Unresolved Issues", Cooper TB, Gershon S, Kline NS and Schou M (eds) , Amsterdam, pp 703-729.

6. Belmaker RH and Ebstein RP (1979). Adenylate cyclase and the mechanism of lithium action. In: "Neuropsychopharmacology", Saletu B (ed) Pergamon Press, Oxford, pp173-184.
7. Belmaker RH and Ebstein RP. Biochemical genetics and platelet MAO (1979). In: "Neuropsychopharmacology", Saletu B (ed) Pergamon Press, Oxford, pp 95-101.
8. Belmaker RH, Dasberg H and Ebstein RP (1980). Does neuroleptic blocking of dopamine receptors continue after chronic treatment? In: "Endogenous Peptides and Centrally Acting Drugs", Prog. Biochem. Pharmacol. Vol. 16, Levy A et al. (eds) S. Karger, Basel, pp 109-118.
9. Belmaker RH, Zohar J and Ebstein RP. Cyclic nucleotides in mental disorders. In: "Advances in Cyclic Nucleotide Research", Vol. 12, Hamet P and Sands H (eds) Raven Press, New York, 1980, pp. 187-197. Citations: 14
10. Ebstein RP, Eliashar S and Belmaker RH (1980). The effect of chronic lithium on adenylate cyclase and dopamine mediated animal behaviors. In: "Neurotransmitters and Mental Diseases", Youdim MBH and Usdin E (eds) John Wiley, New York, pp 395-409.
11. Lerer B, Ebstein RP and Belmaker RH (1980). Receptor mechanisms of lithium action in affective disorders. In: "Neurotransmitters and Their Receptors", Littauer UZ et al. (eds.) John Wiley, New York, pp 149-153.
12. Belmaker RH, Lerer B, Ebstein RP and Dasberg H (1980). The adrenergic receptor as the locus of antidepressant therapy in humans. In: "Neurotransmitters and Their Receptors", Littauer UA et al. (eds), John Wiley, New York, pp 139-147.
13. Bannet J, Belmaker RH and Ebstein RP (1980). Clinical implications of the molecular model of tardive dyskinesia. In: "Neurotransmitters and Their Receptors", Littauer UZ et al. (eds) John Wiley, New York, pp 155-162.
14. Belmaker RH and Van Praag HM (1980). Mania, disease entity or symptom cluster? In: "Mania, An Evolving Concept", Belmaker RH and Van Praag HM (eds) Spectrum Press, New York, pp 1-5.
15. Belmaker RH, Lerer B and Ebstein RP (1981). Noradrenaline, dopamine and mood. In: "Advances in the Biosciences", Vol. 31, "Recent Advances in Neuropsychopharmacology", Angrist B, Burrows GD, Lader M, Lingjaerde O, Sedvall G and Wheatley D (eds) Pergamon, Oxford, pp 17-29.
16. Eisenberg J, Brecher-Fride E, Weizman R, Ebstein RP and Belmaker RH (1981). Lithium and receptors in an animal model of MBD. In: "Developments in Psychiatry", Vol. 5, Biological Psychiatry, 1981, Perris C, Struwe G and Jansson B (eds) Elsevier, Amsterdam, pp 1010- 1018.
17. Belmaker RH, Lerer B, Zohar J and Birmaher B (1981). Comparison of receptor stabilization and adenylate cyclase theories of lithium action. In: "Developments in Psychiatry", Vol. 5, Biological Psychiatry, 1981, Perris C, Struwe G and Jansson B (eds) Elsevier, Amsterdam, pp 636-644.

18. Belmaker RH, Lerer B and Zohar J (1982). Salbutamol treatment of depression. In: "Typical and Atypical Antidepressants", Costa E and Racagni G (eds) Raven Press, New York, pp 181-193.
19. Belmaker RH, Zohar J and Levy A (1982). Unidirectionality of lithium stabilization of adrenergic and cholinergic receptors. In: "Basic Mechanisms of Lithium Action", Emrich HM and Lux HD (eds) Excerpta Medica, Amsterdam, pp 146-153.
20. Zohar J, Ebstein RP and Belmaker RH (1982). Adenylate cyclase as the therapeutic target site of lithium. In: "Basic Mechanisms of Lithium Action", Emrich HM and Lux HD (eds) Excerpta Medica, Amsterdam, pp 154-166.
21. Bannet J and Belmaker RH (1982). Behavioral and biochemical models of dopamine receptor subsensitivity. In: "Behavioral Models and the Analysis of Drug Action", Levy A and Spiegelstein MY (eds) Elsevier, Amsterdam, pp 449-458.
22. Belmaker RH, Lerer B, Klein E and Hamburger R (1982). The use of behavioral methods in the search for compounds with lithium-like activity. In: "Behavioral Models and the Analysis of Drug Action", Levy A, and Spiegelstein MY (eds) Elsevier, Amsterdam, pp 343-356.
23. Newman M, Zohar J, Kalian M and Belmaker RH (1984). Effects of chronic ECT on adenosine receptor systems in the brain. In: "ECT: Basic Mechanisms", Lerer B, Weiner R and Belmaker RH (eds) John Libbey, London, pp 57-61.
24. Ebstein RP, Lerer B, Shlaufman M and Belmaker RH (1984). The effect of repeated electroconvulsive shock treatment on the release of norepinephrine from rat cortical vesicular preparations. In: "ECT: Basic Mechanisms", Lerer B, Weiner R and Belmaker RH (eds) John Libbey, London, pp 62-66.
25. Lerer B, Stanley M and Belmaker RH (1984). ECT and lithium: Parallels and contrasts in receptor mechanisms. In: "ECT: Basic Mechanisms", Lerer B, Weiner R and Belmaker RH. (eds) John Libbey, London, pp 67-78.
26. Belmaker RH, Lerer B and Klein E (1984). A comparison of carbamazepine with lithium in excited psychoses. In: "Anticonvulsants in Affective Disorders", Emrich HM, Okuma T and Muller AA (eds) Elsevier Science Publishers, pp 198-204.
27. Belmaker RH, Stein D, Weinberger D, Potkin S and Wyatt RJ (1984). Cerebrospinal fluid cyclic nucleotides in schizophrenia. In: "Catecholamines: Neuropharmacology and Central Nervous System - Therapeutic Aspects", Usdin E, Carlsson A, Dahlstrom A and Engel J (eds) Alan R. Liss, New York, pp 173-178.
28. Hamburger-Bar R and Belmaker RH (1984). Dose-response relationships of vasopressin effect on conditioned avoidance learning in a rat model of minimal brain dysfunction. In: "Symposium on Neuronal Communications", Meyer BJ and Kramer S (eds) AA Balkema, Cape Town, pp 138- 144.
29. Belmaker RH, Zohar J and Newman M (1984). The effects of lithium on adenylate cyclase and neurotransmitter receptors. In: "Symposium on Neuronal Communications", Meyer BJ and Kramer S (eds) AA Balkema, Cape Town, pp 223- 231.

30. Gologorsky-Chazan S, Golan P, Kugelmass S and Belmaker RH (1984). The effect of lithium treatment in humans on psychophysiological increases and decreases in heart rate. In: "Current Trends in Lithium and Rubidium Therapy", Corsini G (ed), MTP Press, London, pp 263-273.
31. Belmaker RH, Hamburger-Bar R, Newman M and Bannet J (1984). The effect of rubidium and lithium on adenylate cyclase and neurotransmitter receptors. In: "Current Trends in Lithium and Rubidium Therapy", Corsini G (ed), MTP Press, London, pp 59-75.
32. Hamburger-Bar R, Gak S and Belmaker RH (1984). The effect of a vasopressin derivative on conditioned avoidance learning in a rat model of minimal brain dysfunction. In: "Biological Psychiatry: Recent Studies", Burrows GD et al (eds) John Libbey, London, pp 108-113.
33. Belmaker RH, Elami A and Bannet J (1985). Intermittent treatment with droperidol, a short-acting neuroleptic, increases behavioral dopamine receptor sensitivity. In: "Dyskinesia, Research and Treatment", Casey DE, Chase T, Christiansen AV and Gerlach J (ed) pp 194- 199.
34. Belmaker RH, Eisenberg J, Hamburger R, Mandel B, Chazan S, Shapira Y, Greenberg L, and Shapiro E (1985). Vasopressin effects on learning in 6-OH dopamine treated rats and minimal brain dysfunction children. In: "Psychopharmacology: Impact on Clinical Psychiatry", Morgan DW (ed), Ishiyaku EuroAmerica Inc., St. Louis, Missouri, pp 175-191.
35. Belmaker RH, Klein E and Dick E (1985). Ethics and psychopharmacologic research. In: "Psychopharmacology: Impact on Clinical Psychiatry", Morgan DW (ed) Ishiyaku EuroAmerica Inc, St. Louis, Missouri, pp 19- 29.
36. Zohar J, Greenberg D and Belmaker RH (1985). Blood levels of neuroleptic drugs and their relevance for clinical practice. In: "Psychopharmacology: Impact on Clinical Psychiatry", Morgan DW (ed) Ishiyaku EuroAmerica Inc, St. Louis, Missouri, pp 115-138.
37. Belmaker RH, Klein E and Lerer B (1985). Carbamazepine in excited psychoses. In: "Psychiatry, The State of the Art", Vol. 3: Pharmacopsychiatry, Pichot P, Berner P, Wolf R and Thau K (eds) Plenus Press, New York, pp 485- 489.
38. Newman M, Belmaker RH, Hamburger-Bar R and Lerer B (1986). Receptor-mediated and independent effects in the actions of lithium and electroconvulsive shock on adenylate cyclase. In: "Drug Receptors and Dynamic Processes in Cells", Alfred Benzon Symposium 22, Schou JS, Geisler A, Norn S (eds) Copenhagen, pp 290-301.
39. Zohar J, Lerer B and Belmaker RH (1986). Tricyclic-resistant depression: Responses to receptor manipulation with salbutamol, propranolol, estrogen and vasopressin. In: "Biological Psychiatry 1985", Shagass C et al (eds) Elsevier.
40. Baron M, Belmaker RH and Risch N (1986). X-linkage and bipolar disorders: New strategies. In: "Biological Psychiatry 1985", Shagass C et al (eds) Elsevier, pp 13-15.

41. Oppenheim G, Zohar J, Shapira B and Belmaker RH (1987). Estrogen as a possible treatment for women with resistant depression. In: "Treating Resistant Depression", Zohar J and Belmaker RH (eds) Spectrum Press, New York, pp 357-365.
42. Zohar J, Lerer B and Belmaker RH (1987). Beta-adrenergic agonist as a potential treatment for resistant depression. In: "Treating Resistant Depression", Zohar J and Belmaker RH (eds) Spectrum Press, New York, pp 375- 380.
43. Schreiber G, Avissar S, Umansky R, Perelman GN and Belmaker RH (1988). Implications of muscarinic receptor heterogeneity for research on tardive dyskinesia. In: "Tardive Dyskinesia: Biological Mechanisms and Clinical Aspects", Wolf ME and Mosnaim AD (eds) APA Press, pp 23-28.
44. Avissar S, Schreiber G, Danon A and Belmaker RH (1988). Lithium effects on cyclic AMP and phosphatidylinositol metabolism may promote adrenergic-cholinergic balance. In: "New Developments in Lithium Research", Birch NJ (ed) IRL Press, pp 213-216.
45. Belmaker RH and Roitman G (1988). A clinical trial of demethylchlortetracycline as a lithium-like agent in excited psychoses. In: "Lithium: Inorganic Pharmacology and Psychiatric Use", Birch NJ (ed) IRL Press, pp 191-193.
46. Avissar S, Schreiber G, Danon A and Belmaker RH (1989). Lithium inhibition of noradrenergic-sensitive adenylate cyclase may be mediated by inhibition of G-protein activation. In: "Progress in Catecholamine Research: Clinical Aspects", Belmaker RH (ed.) Alan R. Liss Inc, pp 23-88.
47. Belmaker RH, Benjamin J, Kaplan Z and Roitman G (1989). A comparison of theories of lithium action based on phosphatidylinositol metabolism with theories based on cyclic AMP. In: "New Directions in Affective Disorders", Lerer B and Gershon S (eds) Springer-Verlag, New York, pp 134-137.
48. Belmaker RH, Avissar S, Schreiber G, Kaplan Z, Givant Y, Lichtenberg P and Zohar J (1990). Does the effect of lithium on G-proteins have behavioral correlates? In: "Lithium and Cell Physiology", Bach RO and Gallicchio VS (eds) Springer-Verlag, New York, pp 94-101.
49. Belmaker RH, Livne A, Agam G, Moscovich D, Grisaru N, Schreiber G, Avissar S, Danon A. and Kofman O (1990). "The role of inositol-1-phosphatase inhibition in the mechanism of action of lithium". *Pharmacology & Toxicology* 66 (suppl III): 76-83.
50. Belmaker RH, Zohar J and Klein E (1990). Are the effects of carbamazepine on blood levels of haloperidol clinically relevant? In: "International Clinical Psychopharmacology", Emrich H, Schiwy W and Silverstone T (eds) Clinical Neuroscience Publishers, London, 5 (suppl 1): 67-72.
51. Kofman O and Belmaker RH (1991). Animal behavioral models of mania and bipolar affective illness. In: "Animal Models of Psychiatric Disorder: Anxiety, Depression and Mania", Soubrie P (ed) Karger, Basel, Vol 3 pp 103-121.

52. Belmaker RH, Avissar S and Schreiber G (1991). Effects of lithium on human neurotransmitter receptor systems and G-proteins. In: "Lithium and the Cell: Pharmacology and Biochemistry". Birch NJ (ed), Academic Press, Ltd., London, pp 113-119.
53. Kofman O, Belmaker RH (1991). Oral or ICV injection of compounds that reduce cyclic AMP affect rat behavior. In: Biological Psychiatry Volume 1, G Racagni, N Brunello, T Fukuda (eds), Elsevier Science Publishers, Amsterdam, pp 195-196.
54. Kofman O, Belmaker RH (1991). Intracerebroventricular inositol does not reverse high dose lithium toxicity in rats. *Clinical Neuropharmacology* 13 (suppl 2): 211-212.
55. Belmaker RH, Revasov A, Bersudsky Y, Kofman O (1992). Inositol passes the blood brain barrier sufficiently to reverse lithium effects on behavior in rats. *Clinical Neuropharmacology* 15 (suppl 1): 606-607.
56. Kofman O, van Embden S and Belmaker RH (1993). Tetracycline derivatives as potential lithium-like compounds. Birch NJ, Padgham C and Hughes MS (eds), Lithium in Medicine and Biology. Marius Press, Lancashire, pp 151-164.
57. Levine J, Gonsalves M, Belmaker RH (1993). Inositol modulation of second messenger systems: a strategy for psychopharmacology of depression in aging. Bergener M, Belmaker RH and Tropper M (eds) Psychopharmacotherapy in Old Age. Springer, New York, pp 254-260.
58. Bersudsky Y, Vinnitsky I, Grisaru N, Kofman O and Belmaker RH (1993). Dose-response and time-curve of inositol prevention of Li-pilocarpine seizures. *European Neuropsychopharmacology* 3 (special issue): 428-429.
59. Belmaker RH (1994). Inositol (Plenary Lecture extended abstract). *European Neuropsychopharmacology* 4: 165-166.
60. Kofman O, Belmaker RH, Mork A and Geisler A (1994). The 4-dedimethylamino derivative of tetracycline loses both ability to block cyclic AMP accumulation and the ability to inhibit rat motor activity. *European Neuropsychopharmacology* 4: 420-421.
61. Grisaru N, Yaroslavsky U, Abarbanel J, Lamberg T, Belmaker RH (1994). Transcranial magnetic stimulation in depression and schizophrenia. *European Neuropsychopharmacology* 4: 287-288.
62. Fleischmann A, Steppel J, Leon A, Belmaker RH (1994). The effect of transcranial magnetic stimulation compared with electroconvulsive shock on rat apomorphine-induced stereotypy. *European Neuropsychopharmacology* 4: 449-450.
63. Levine J, Pomerantz T, Belmaker RH (1994). The effect of inositol on cognitive processes and mood states in normal volunteers. *European Neuropsychopharmacology* 4: 418-419.
64. Barak Y, Levine J and Belmaker RH (1994). The effect of inositol on lithium induced EEG abnormalities. *European Neuropsychopharmacology* 4: 419-420.

65. Bersudsky Y, Mahler O, Kofman O and Belmaker RH (1994). Species differences in susceptibility to Li-pilocarpine seizures. *European Neuropsychopharmacology* 4: 429-430.
66. Agam G, Kofman O and Shapiro J (1994). Icv inositol does not reverse seizures elicited by an inositol monophosphatase inhibitor K-76CONa and pilocarpine. *European Neuropsychopharmacology* 4: 424-425.
67. Agam G, Bersudsky Y and Kofman O (1994). The effect of chronic peripheral administration on Li-pilocarpine seizures and rat brain inositol levels. *European Neuropsychopharmacology* 4: 417.
68. Belmaker RH, Bersudsky Y, Benjamin J, Agam G, Levine J, Kofman O (1995). Manipulation of inositol-linked second messenger systems as a therapeutic strategy in psychiatry. In: Gessa GL, Fratta W, Pani L and Serra G (eds) *Depression and Mania: From Neurobiology to Treatment*. Raven Press, New York pp 67-84.
69. Benjamin J, Agam G, Levine J, Bersudsky Y, Kofman O, Belmaker RH (1995). Inositol treatment in Psychiatry. *Psychopharmacology Bulletin* 31: 167-175.
70. Grisaru N, Abarbanel J, Belmaker RH (1995). Slow magnetic stimulation of motor cortex and frontal lobe in depression and schizophrenia. *Acta Neuropsychiatrica* (special issue). 7: S21-S23.
71. Belmaker RH, Agam G (1995). Social context, the biology of suicide, and second messengers. *Clinical Neuropharmacology* 18 (suppl 3): S34-S38.
72. Belmaker RH, Bersudsky Y, Agam G, Levine J, Kofman O (1996). How does lithium work on manic-depression?: clinical and psychological correlates of the inositol theory. *Annual Review of Medicine: Selected Topics in the Clinical Sciences*. Vol 17, pp 47-56, Annual Reviews Inc, Palo Alto, California, USA.
73. Benjamin J, Fux M, Belmaker RH (1996). Time course of inositol treatment of panic disorder. *European Neuropsychopharmacology* 6 (suppl 4): S48-S49.
74. Benjamin J, Ebstein RP, Belmaker RH (1997). Personality Genetics. *Isr J Psychiatry Rel Sci* 34: 270-280.
75. Hertz L, Wolfson M, Hertz E, Agam G, Richards M and Belmaker RH (1997). Lithium-inositol interactions: synthesis, uptake turnover. In: Honig A, Ansseau M, van Praag HM (eds). *Depression: Neurobiological, Psychopathological and Therapeutic Advances*, pp 519-534. John Wiley and Sons Ltd, England.
76. Belmaker RH, Grisaru N, Ben-Shahar D, Klein E (1997). The effects of TMS on animal models of depression, β -adrenergic receptors, and brain monoamines. *CNS Spectrums* 2: 26-30.
77. Belmaker RH, Grisaru N. (1998) Magnetic stimulation of the brain in animal depression models responsive to ECS. *Journal of ECT* 14:194-205.
78. Nemanov L, Ebstein RP, Shamir A, Atack JR, Levine J, Osher Y, Belmaker RH, Agam G. Effects of bipolar disorder and lithium treatment on inositol

- monophosphatase transcription and translation. In: Birch NJ, Gallicchio VS, Becker RW (eds). *Lithium: 50 Years of Psychopharmacology*. Weidner Publishing, Cheshire, Connecticut, 1999 pp 116-135.
79. Pridmore S, Belmaker RH (1999). TMS treatment of psychiatric disorder. *Psychiatry and Clinical Neuroscience* 53:541-548.
 80. Bersudsky Y, Einat H, Stahl Z, Belmaker RH (1999). Epi-inositol and inositol depletion: two new treatment approaches in affective disorder. *Current Psychiatry* 1:141-147.
 81. Grisaru N, Chudakov B, Yaroslavsky Y, Belmaker RH. Is TMS therapeutic in mania as well as depression? In: Paulus W, Hallett M, Rossini PM and Rothwell JC (eds.). *Transcranial Magnetic Stimulation*. Elsevier, Netherlands, 1999, pp 299-303.
 82. Benjamin J, Belmaker RH. Psychiatric genetics in Israel. (1999). *Psychiatric Genetics* 9:53-57.
 83. Grisaru N, N Yaroslavsky Y, Belmaker RH. Is TMS an antibipolar treatment? In: George MS and Belmaker RH (eds). *Transcranial Magnetic Stimulation (TMS) in Neuropsychiatry*. APA Press, 2000, pp 201-208.
 84. Ebstein RP, Benjamin J, Belmaker RH (2000). Personality and polymorphisms of genes involved in aminergic neurotransmission. *European J of Pharmacology* 410:205-214.
 85. Belmaker RH, Einat H, Levkovitz Y, Segal M, Grisaru N. TMS effects on animal models of depression and mania: implications of hippocampal electrophysiology? In: George MS and Belmaker RH (eds). *Transcranial Magnetic Stimulation (TMS) in Neuropsychiatry*. APA Press, 2000, pp 99-114.
 86. Levine J, Barak Y, Benjamin J, Bersudsky Y, Kofman O and Belmaker RH. Therapeutic potential of inositol treatment in depression, panic, dementia and lithium side effects. In: Montgomery S and Halbreich U (eds) *Pharmacotherapy of Mood, Anxiety and Cognition*. American Psychiatric Press, 2000. pp 159-166.
 87. Fleischmann A, Silverberg D, Belmaker RH. (2000). Antidepressant potential of transcranial magnetic stimulation in rat models: comparison of slow versus rapid magnetic stimulation. In: Montgomery S and Halbreich U (eds) *Pharmacotherapy of Mood, Anxiety, and Cognition*. American Psychiatric Press, 2000. pp 189-196.
 88. Belmaker RH, Yaroslavsky Y. Perspectives for New Pharmacological Interventions. In: Gershon S and Soares J (eds). *Basic Mechanisms and Therapeutic Implications of Bipolar Disorder*. Marcel Dekker, Inc., New York, NY, 2000. pp 507-528.
 89. Einat H, Shaldubina A, Belmaker RH. Epi-inositol: a potential antidepressant In: *Drug Development Research, special issue, Biotechnology and Drug Development in Israel*. Wiley-Liss, New York, 2000, pp309-315.
 90. Ebstein RP, Benjamin J, Belmaker RH (2000). Genetics of personality dimensions. *Current Opinion in Psychiatry* 13:617-622.

91. Lisanby SH, Belmaker RH. (2000). Animal models of the mechanisms of action of repetitive transcranial magnetic stimulation (rTMS): comparisons with electroconvulsive shock (ECS). *Depression and Anxiety* 12:178-187.
92. Einat H, Kofman O, Belmaker RH. Animal Models of Bipolar Disorder: From A single Episode to Progressive Cycling Models. In: Myslobodsky MS and Weiner I (eds). *Contemporary Issues in Modeling Psychopathology*. Kluwer Academic, Boston, MA. 2000, pp165-179.
93. Einat H, Belmaker RH (2001). The effects of inositol treatment in animal models of psychiatric disorders. *Journal of Affective Disorders* 62:113-121. Citations: 32
94. Nemets B, Belmaker RH, Fux M, Levine J (2001). Combination of antidepressant drugs: the case of inositol. *Human Psychopharmacology Clin Exp* 16:37-43.
95. Einat H, Belmaker RH. Mechanisms of inositol effects on behavior In: *Contemporary Neuropsychiatry*, Miyoshi K, Shapiro CM, Gaviria M, Morita Y (eds). Springer Verlag. Tokyo, Japan, 2001, pp252-256.
96. Grisaru N, Yaroslavsky, Belmaker RH. TMS in mania and in animal models of mania In: *Contemporary Neuropsychiatry*, Miyoshi K, Shapiro CM, Gaviria M, Morita Y (eds). Springer Verlag. Tokyo, Japan, 2001, 233-236.
97. Benjamin J, Ebstein RP, Belmaker RH (2001). Genes for human personality traits: "endophenotypes" of psychiatric disorders? (editorial) *World J of Biological Psychiatry* 2:54-57.
98. Einat H, Belmaker RH. (2001). Animal models of psychiatric diseases *Harefuah* 140:458-463, 568.
99. Ebstein R, Belmaker RH. Genetics of sensation or novelty seeking and criminal behavior In: *The Neurobiology of Criminal Behavior*, Glicksohn J (ed). Kluwer Academic Publishers. Boston, USA, 2002, 51-78.
100. Benjamin J, Belmaker RH. Inositol in treatment of psychiatric disorders In: Mischoulon D and Rosenbaum JF (eds). *Alternative Medications and the Treatment of Psychiatric Disorders*. Lippincott Williams & Wilkins, Baltimore, MD, 2002, 111-124.
101. Benjamin J, Ebstein RP, Belmaker RH. Personality Genetics, (2002). *Israel Journal of Psychiatry* 39:271-279.
102. Levine J, Bersudsky Y, Nadri C, Yaroslavsky Y, Abed N, Mishory A, Agam G, Belmaker RH. Mechanism of action of new mood stabilizing drugs In: *Handbook of Medical Psychiatry*. Soares JC and Gershon S (eds) Marcel Dekker, New York, 2003, 793-806.
103. Shaldubina A, Belmaker RH, Agam G. Multiple mechanisms of action of lithium In: *Handbook of Medical Psychiatry*. Soares JC and Gershon S (eds), Marcel Dekker, New York, 2003, 757-766.
104. Belmaker RH, Bersudsky Y (2003). A rational approach to the use of atypical antipsychotics (editorial). *Israel Journal of Psychiatry* 40:79-81.

105. Agam G, Shatiel G, Kozlovsky N, Shimon H, Belmaker RH (2003). Lithium inhibitable enzymes in postmortem brain of bipolar patients. *J Psychiatric Res* 37:433-442.
106. Belmaker RH, Mishory A, Bersudsky Y (2003). Anticonvulsant prophylaxis in bipolar disorder: is phenytoin the prototype? *European Neuropsychopharmacology* 13:S106-107.
107. Greenberg ML, King D, Shaltiel G, Ju S, Agam G, Belmaker RH (2003). Inhibition of myo-inositol-phosphate synthase by valproate: a mechanism for mood stabilization? *European Neuropsychopharmacology* 13: 107-108.
108. Einat H, Belmaker RH, Manji HK (2003). New approaches to modeling bipolar disorder. *Psychopharmacol Bull*, 37:47-63.
109. Belmaker RH, Bersudsky Y (2003). Introduction: Mechanism of atypicality of antipsychotic drugs. *Progress in Neuro-Psychopharmacology & Biological Psychiatry*, 27:1067-1069.
110. Nemets B, Osher Y, Belmaker RH (2004). Omega-3 fatty acids and augmentation strategies in treating resistant depression. *Essential Psychopharmacology* 6:57-62.
111. Belmaker RH, Bersudsky Y. Bipolar disorder: mania and depression. *Discovery Medicine* 24:239-245.
112. Shamir A, Agam G, Belmaker RH (2004). Neurogenesis and neuroprotection as new drug targets for bipolar patients: a critical review In: *Current and Future Developments in Psychopharmacology*. den boer JA, ter Horst GJ, George M (eds). Organon, The Netherlands, 217-230.
113. Belmaker RH, Bersudsky Y (2004). Bipolar disorder: treatment. *Discovery Medicine* 24:415-420.
114. Belmaker RH, Agam Galila (2004). Introduction In: *Special Issue: Lithium and Mood Stabilizers: Mechanisms of Action*. Belmaker RH & Agam G (eds). *Clinical Neuroscience Research* 4:133-135.
115. Belmaker RH, Agam G (2005). Bipolar disorder: neurochemistry and drug mechanisms. *Discovery Medicine* 5:191-198.
116. Levine J, Sela B-A, Osher Y, Belmaker RH. (2005). High homocysteine serum levels in young male schizophrenia and bipolar patients and in an animal model, In: *Homocysteine in Psychiatry: State of the Art*. *Progress in Neuro-Psychopharmacology & Biological Psychiatry*, Elsevier 29:1181-91.
117. Levine J, Belmaker RH, Bottiglieri (2005). Introduction In: *Homocysteine in Psychiatry: State of the Art*. *Progress in Neuro-Psychopharmacology & Biological Psychiatry*, Elsevier 29: 1101-1102.
118. Belmaker RH, Shaldubina A, Bersudsky Y. (2006). Effects of lithium on behavior and cognition (animals and health humans) In: *Lithium in Neuropsychiatry: The Comprehensive Guide*. Bauer M, Grof P & Muller-Oerlinghausen B (eds). Taylor & Francis Books Ltd, United Kingdom. 433-439.

119. Levine J, Applebaum J, Belmaker RH. (2006). Novel treatments of bipolar depression In: Bipolar Depression. El-Mallakh RS, Ghaemi N (eds). APPI Press, Washington DC. 191-214.
120. Ebstein RP, Bachner-Melman R, Benjamin J, Belmaker RH (2006). The elusive world of personality genes: cherchez le phenotype In: Neurobehavioral Genetics: Methods and Applications 2nd edition, Jones BC, Mormede P (eds). Taylor & Francis, pp 263-279.
121. Einat H, Shaldubina A, Bersudsky Y, Belmaker RH (2007). Prospects for the Development of Animal Models for the Study of Bipolar Disorder. In: Basic Mechanisms and Therapeutic Implications of Bipolar Disorder, 2nd edition. Soares J and Young A (eds). Marcel Dekker, Inc., New York, NY. 19-31.
122. Grisar N, Chudakov B, Kaptan A, Shaldubina A, Applebaum J, Belmaker RH (2007). TMS in mania In: TMS in Clinical Psychiatry. George M, Belmaker RH (eds). APPI Press, Washington DC. 153-163.
123. George M, Belmaker RH (2007). Epilogue for the clinician In: TMS in Clinical Psychiatry. George M, Belmaker RH (eds). APPI Press, Washington DC. 257-264.
124. Belmaker RH, Bersudsky Y (2007). Lithium-pilocarpine seizures as a model for lithium action in mania In: Animals Models of Bipolar Disorder and Mood Stabilizer Efficacy. Gould T and Einat H (eds). *Neuroscience & Biobehavioral Reviews*, 31:843-849.
125. Belmaker RH, Agam G, Lenox RH (2007). Neurobiology and pharmacotherapy of bipolar disorder In: Handbook of Contemporary Neuropharmacology. Sibley D, Hanin I, Kuhar M, Skolnick P (eds). APPI Press, 859-876.
126. Belmaker RH (2007). Mood stabilizers (Hebrew) In: Israel Medical Encyclopedia, Vol 8. Sheinfeld Y (ed). Idiot Achronot Books, Tel Aviv, 1767
127. Grisar N, Chudakov B, Kaptan A, Shaldubina A, Applebaum J, Belmaker RH (2008). TMS in bipolar disorder In: Oxford Handbook of Transcranial Stimulation. Wassermann E, Epstein C, Ziemann U, Lisanby S, Paus T & Walsh V(eds). Oxford University Press 661-669.
128. Belmaker RH, Nemets B (2008). Introduction In: Alternative Treatments in Mental Health (special issue). Belmaker RH, Nemets B (eds). *Israel Journal of Psychiatry* 45:1-2.
129. Belmaker RH, Levine J, Agam G (2008). Future of depression psychopharmacology (Hebrew). *Medicine* 24-27.
130. RH Belmaker (2008). Future of depression psychopharmacology. *CNS Spectrums* 13:682-687.
131. Belmaker RH, J Levine. (2008). Inositol in treatment of psychiatric disorders In: Alternative Medications and the Treatment of Psychiatric Disorders. (2nd edition). Mischoulon D and Rosenbaum JF (eds). Lippincott Williams & Wilkins, Baltimore, MD, 105-115.

132. Levine J, Belmaker RH (2009). Genetic epidemiology of schizophrenia in Arab communities in Israel In: *Epidemiology of Psychiatric Disorders and Behavioral Disorders in Israel*. Levav I (ed). Gefen Publishing, Jerusalem. 254-266.
133. Belmaker RH (2010). The limits of scientific understanding and their relevance for the role of religion in psychiatry In: *Psychiatry and Religion: Beyond Boundaries*. Verhagen PJ, van Praag HM, Lopez-Ibor JJ, Cox JL, Moussaoui D (eds). John Wiley & Sons Ltd, London. 515-521.
134. Agam G, Bersudsky Y, Belmaker RH (2009). Abnormalities of inositol metabolism in lymphocytes as biomarkers for bipolar disorder In: *Neuropsychiatric Biomarkers, Endophenotypes, and Genes: Promises, Advances, and Challenges*. Ritsner M (ed). Springer Science 191-195.
135. Belmaker RH (2009). Afterword In: *Neuropsychiatric Biomarkers, Endophenotypes, and Genes: Promises, Advances, and Challenges*. Ritsner M (ed). Springer Science 211-214.
136. Belmaker RH. Bipolar disorder In: *Encyclopedia of Psychopharmacology*. Stolerman I. (ed). (in press).
137. Lichtenberg P, Belmaker RH (2009). Deconstruction of major depression. *Frontiers in Neuroscience* 3:234-235.
138. Lichtenberg P, Belmaker RH (2010). Has the Diagnosis of Major Depressive Disorder Outlived Its Usefulness? (Hebrew). *Medicine* (Publication of The Medical Group) 12:20-25.
139. Belmaker RH, Lichtenberg P (2010). Classification in psychiatry In: *Psychiatry: An Evidence Based Text for the MRCPsych*. Puri B & Treasaden I (eds). Hodder & Stoughton Limited, London. 489-498.
140. Belmaker RH (2010). Transcranial Magnetic Stimulation and Vagus Nerve Stimulation In: *Psychiatry: An Evidence Based Text for the MRCPsych*. Puri B & Treasaden I (eds). Hodder & Stoughton Limited, London. p931-933.
141. Belmaker RH, Agam G (2010). The Effect of Lithium on Adenylyl Cyclase: Thirty-Five Years of Research (1975-2010). *Clinical Psychopharmacology and Neuroscience* 8:127-132.
142. Belmaker RH (2010). A yes or no answer (commentary). *World Psychiatry* 9:166-7.
143. Toker L, Belmaker RH, Agam G (2012). Gene expression studies in understanding the mechanism of action of lithium. *Expert Review of Neurotherapeutics* 12:93-97.
144. Belmaker RH, Arbelle S (2012). Editorial in Special Issue (part 1): Pediatric Bipolar Disorder, *Israel Journal of Psychiatry*, 49:2.
145. Meiri G, Belmaker RH (2013). Omega- 3 Fatty Acids in the Treatment of Autism Spectrum Disorder In: *Comprehensive Guide to Autism*. Patel VB, Preedy VR, Martin CR (eds). Springer.

1. Belmaker RH, and Wald D (1977). Haloperidol in normals. *Brit J Psychiat* 131: 222. (letter). Citations: 80
2. Belmaker RH, Reches A and Ebstein RP (1977). K_m of platelet monoamine oxidase in schizophrenia. *Lancet* 2: 821. (letter).
3. Belmaker RH, Galon A, Perez L and Ebstein RP (1977). Platelet MAO in schizophrenics with and without family history of schizophrenia. *Brit J Psychiat* 131: 551- 552. (letter).
4. Durst M and Belmaker RH (1978). The Son of Sam and Psychiatric hospitalization. *Am J Psychiat* 135: 131. (letter).
5. Ruskin P, Averbuch I, Belmaker RH and Dasberg H (1979). Benzo-diazepines in chronic schizophrenia. *Biol Psychiat* 14: 557-558. (letter).
6. Gagrut D, Maggiano J and Belmaker RH (1979). Effect of neuroleptic treatment in schizophrenia on the electroretinogram, electrooculogram and color vision. *Psychiat Res* 1: 109. (letter).
7. Bannet J, Ebstein RP and Belmaker RH (1979). Salivary lithium. *Brit J Psychiat* 135: 446. (letter).
8. Braha H, Ebstein RP and Belmaker RH (1979). Mechanism of lithium effect in bronchial asthma. *Am J Psychiat* 136: 734. (letter).
9. Bannet J, Ebstein RP and Belmaker RH (1980). Clinical aspects of the interaction of lithium and stimulants. *Brit J Psychiat* 136: 204. (letter).
10. Belmaker RH, Lerner Y and Ebstein RP (1980). Titrated versus fixed-dose protocols. *Am J Psychiat* 137: 257. (letter).
11. Belmaker RH, Lerner Y and Ebstein RP. Rapid neuroleptization reconsidered. *Am J Psychiat* 137: 129, 1980.(letter).
12. Bannet J, Gillis S, Ebstein RP and Belmaker RH (1981). Presentation d'un modele moleculaire des dyskinesies tardives (Didactic review, in French). *French Medical Journal AMIF* 29 (300): 898-901.
13. Belmaker RH (1982). Report of the 13th International Neuropsychopharmacology Congress (in Hebrew). *Harefuah: J Israel Med Assoc* 103: 221-22.
14. Belmaker RH (1983). Generations of the Holocaust. Bergmann and Jucovy, (eds.) Book review. *Am J Psychiat* 40: 1090 and correspondence *Am J Psychiat* 141: 826, (1984).
15. Belmaker RH (July 1984). Advisor's Comment. (Editorial Introduction). *Medicine Int*, Israel Edition, Series 1: 33. "Psychiatric Disorders".
16. Belmaker RH (1986). It's good to get off the couch. *Yachad*, Feb. 21, p. 16.

17. Belmaker RH (1986). *Le Roi est nu*. (French) Jerusalem: Revue psychanalytique et culturelle 1: 78-88.
18. Benjamin J and Belmaker RH (1988). A case of promiscuity. *Israel Journal of Psychiatry and Related Sciences* 25: 56- 61.
19. Belmaker RH, Bleich A and Grinshpoon A (June 1989). Adult enuresis: A review. (in Russian, a revision and translation). *Korsakoff Journal of Psychiatry*, pp. 131-135.
20. Belmaker RH, Prywes M (1992). Israel: problems and solutions. In: Masserman HJ and Christine McGuire Masserman (eds). "Social Psychiatry and World Accords", Gardener Press Inc, New York, pp 169-172.
21. Belmaker RH, Chapman J, Shimon H, Korczyn A (1992). Absence of prion protein mutation in bipolar manic-depressive patients of Libyan and non-Libyan Jewish origin. *Brit J Psychiatry* 161: 132. (letter).
22. Grisaru N and Belmaker RH (1994). Lithium and inositol levels. *British Journal of Psychiatry* 164: 133-134. (letter).
23. Amital D and Belmaker RH (1994). Lithium involvement in physostigmine-induced seizures. *Biological Psychiatry* 36: 498.
24. Lokshin P, Prolov K, Belmaker RH (1994). A survey of insulin coma experience among former Soviet psychiatrists in Israel. *Human Psychopharmacology* 9: 307. (letter)
25. Matar M, Lokshin P and Belmaker RH (1995). Treatment of psychosis and tardive dyskinesia with remoxipride. *Harefuah* (in Hebrew) 128: 30. (Case report).
26. Grisaru N, Chudakov B, Yaroslavsky Y, Belmaker RH (1998) Catatonia treated with transcranial magnetic stimulation. *American Journal of Psychiatry* 155:1630. (letter).
27. Lokshin P, Lerner V, Miodownik C, Dobrusin M, Belmaker RH (1999) Parenteral clozapine: Five years experience. *J Clin Psychopharmacol* 19:479-478 (letter).
28. Dobrusin M, Lokshin P, Belmaker RH. (1999). Acute olanzapine overdose: a case report. *Human Psychopharmacology* 14:355-356.
29. Gelber D, Belmaker RH (1999). Tardive dyskinesia with quetiapine. *Am J Psychiatry* 5:796-797 (letter).
30. Belmaker RH. (1999) Clinton, sex, and psychiatry? *Am J Psychiatry* 9:1472-1473 (letter).
31. Nemets B, Geller V, Grisaru N, Belmaker RH. (2000). Olanzapine treatment of clozapine induced NMS. *Human Psychopharmacology* 15:77-78. Citations: 3
32. Belmaker RH (2000). Catalyzing biological psychiatry in Jerusalem. In: The Triumph of Psychopharmacology and the Story of CINP. TA Ban, D Healy, E Shorter (eds). Animula Publishing House, Hungary. Pp 182-185.

33. Belmaker RH (2002). The 1982 CINP congress in Jerusalem In: From Psychopharmacology to Neuropsychopharmacology in the 1980's: The Story of the CINP as told in autobiography. Ban T, Healy D, Shorter E (editors) Animula Publishing House, Budapest p376-379.
34. RH Belmaker (2002). Obituary: Seymour Kety. *Israel J of Psychiatry* 39:65.
35. Belmaker RH. Syndromes, symptoms and spectra (commentary) In: *Bipolar Disorder*, Maj M, Akiskal H, Lopez-Ibor J, Sartorius N (eds). Wiley and Sons, Ltd, New York, USA, 2002, 93-94.
36. Yaroslavsky Y, Stahl Z, Belmaker RH (2002). Ketogenic diet in bipolar illness. *Bipolar Disorders* 4:75 (letter).
37. Belmaker RH, Fitzgerald P, George MS, Lisanby SH, Pascual-Leone A, Schlaepfer TE, Wassermann E. (2003). Managing the risks of repetitive transcranial stimulation. *CNS Spectrums* 8:489 (letter).
38. Belmaker RH. Evidence vs. experience in eating disorder In: *Bipolar Disorder*, Maj M, Halmi K, Lopez-Ibor J, Sartorius N (eds). Wiley and Sons, Ltd, New York, USA, 2003, 301-310.
39. Levine J, Belmaker RH. (2004). Response to de Haan et al. On: elevated homocysteine levels in young male schizophrenics. *American Journal of Psychiatry* 161:1132 (letter).
40. Shaltiel G, Shamir A, Agam G, Belmaker RH (2005). Only tryptophan hydroxylase (TPH)-2 is relevant to the CNS. *Am J Med Genet B Neuropsychiatr Genet* 136:106 (letter).
41. Belmaker RH. (2004). Passion Lost: Public Sex, Private Desire in the Twentieth Century by Patricia Anderson. *Archives of Sexual Behavior* 33:71-71 (book review).
42. Shaldubina A, Einat H, Bersudsky Y, Belmaker RH (2005). Epi-inositol is ineffective in porsolt forced swim test of depression. *Neuropsychiatric Disease and Treatment* 1:189-190.
43. Levine J, Belmaker RH (2006). Homocysteine and osteoporosis. *Am J Psychiatry* 163:549-50 (letter). Citations: 2
44. Belmaker RH (2006). Sex work during the World Cup in Germany *Lancet* 2;368(9538):841 (letter).
45. Belmaker RH, El Katnani O, Tiyano S (2006). Report on the 2005 Cairo Meeting of the World Psychiatric Association. *Harefua* (in Hebrew) 148; 76.
46. Belmaker RH (2007). Bipolar psychopharmacotherapy: caring for the patient. Marneros A, Goodwin FK (eds) Cambridge University Press, *Am J Psychiatry* 164; 353-354 (book review).

47. Belmaker RH (2008) Psychotic Depression by Conrad M. Swartz & Edward Shorter. *New England Journal of Medicine* 358; 435 (book review).
48. Belmaker RH (2008). Antidepressant medications and other treatments of depressive disorders: a CINP Task Force report based on a review of evidence. *International Journal of Neuropsychopharmacology* 11: 577-8 (letter).
49. Belmaker RH, Nemets B (2008). Alternative treatments in mental health. *Israel Journal of Psychiatry* 45:1-2 (editorial).
50. Belmaker RH, Agam G, Bersudsky Y (2008). Role of GSK3b in behavioral abnormalities induced by serotonin deficiency. *PNAS* 105(20):E23 (letter).
51. Belmaker RH (2008). Commentary on: Big pharma and health care: unsolvable conflict of interests between private enterprise and public health by Brezis M. *Israel Journal of Psychiatry* 45:90-91.
52. Belmaker RH, Bersudsky Y (2008). Lithium and pregnancy, Comment on: Is lithium a real teratogen? What we can conclude from the prospective versus retrospective studies by Yacobi and Ornoy. *Israel Journal of Psychiatry* 45:299 (letter).
53. Belmaker RH (2008). Soul in the brain by Michael R. Trimble. *American Journal of Psychiatry* 165: 1361 (book review).
54. Belmaker RH (2008). E-interview by Fannon D: In *Psychiatric Bulletin* 32:120.
55. Bersudsky Y, Belmaker RH (2009). Treatment of bipolar disorder: a systematic review of available data and clinical perspectives' by Fountoulakis & Vieta (2008) (letter). *International Journal of Neuropsychopharmacology* 12:285-6.
56. Belmaker RH (2009). Patient History Must Be Incorporated into any guidelines (letter) *Bipolar Disorders* 11:772.
57. Belmaker RH (2010). (Hebrew). Are placebo controls necessary in psychiatric research? *Medicine* (Publication of The Medical Group) 12: 7.
58. Belmaker RH, Bersudsky Y, Lichtenberg P (2010). Bayesian approach to bipolar guidelines (letter). *World Journal of Biological Psychiatry*. 11(1):76-7.
59. Belmaker RH (2010). The future of anticonvulsants in bipolar disorder (letter). *Bipolar Disorders* 12(1):109-10.
60. Einat H, Anderson GW, Belmaker RH (2010). mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists (letter). *Science* 959-964.
61. Nutt D, Goodwin G (2011). ECNP summit on the future of CNS drug research in Europe 2011 (letter). *European Neuropsychopharmacology* 21:495-499.
62. Belmaker RH (2011) Interviewed by H Van Praag In: An Oral History of Neuropsychopharmacology: The First Fifty Years. Ban T (ed), Create Space, p313-320.

63. Applebaum J, Nemets B, Kaplan Z, Witztum E, Belmaker RH (2012). Prevalence of history of childhood sexual abuse in consecutive hospital admissions of women with psychotic diagnosis. *Psychotherapy and Psychosomatics* (letter) 5:318-319
64. Belmaker RH and Agam G (2012). Deep brain drug delivery. *Brain Stimulation* (letter) 3:455-6.
65. P-Y Lin, D Mischoulon, M P Freeman, Y Matsuoka, J Hibbeln, R H Belmaker and K-P Su (2012). Are omega-3 fatty acids antidepressants or just mood-improving agents? The effect depends upon diagnosis, supplement preparation, and severity of depression. *Molecular Psychiatry* (letter) 17:1161-1163.

Articles in Scientific Journals

1. Belmaker RH, Proctor E and Feather BW (1974). Muscle tension in human operant heart rate conditioning. *Conditional Reflex* 7: 97-106, 1972. Reprinted in "Biofeedback and Self-Control Annual", Miller NE et al. (eds).
2. Wyatt RJ, Saavedra J, Belmaker RH, Cohen S and Pollin W (1973). The dimethyltryptamine-forming enzyme in blood platelets: A study in monozygotic twins discordant for schizophrenia. *Am J Psychiat* 130: 1359-1361.
3. Wyatt RJ, Murphy DL, Belmaker RH, Cohen S, Donnelly CH and Pollin W (1973). Reduced monoamine oxidase activity in platelets: A possible genetic marker for vulnerability to schizophrenia. *Science* 173: 916-918.
4. Belmaker RH, Pollin W, Wyatt RJ and Cohen S (1974). A follow-up of monozygotic twins discordant for schizophrenia. *Arch Gen Psychiat* 30: 219-222.
5. Murphy DL, Belmaker RH and Wyatt RJ (1974). Monoamine oxidase in schizophrenia and other behavioral disorders. *J Psychiatric Res* 11: 221-247.
6. Belmaker RH, Murphy DL, Wyatt RJ and Loriaux DL (1974). Human platelet monoamine oxidase changes during the menstrual cycle. *Arch Gen Psychiat* 31: 553-556.
7. Belmaker RH, Beckman H, Goodwin F, Murphy DL, Pollin W, Buchsbaum M, Wyatt RJ, Ciaranello R. and Lamprecht F (1975). Relationship between platelet and plasma monoamine oxidase, plasma dopamine-beta-hydroxylase and urinary 3-methoxy-4-hydroxy phenyl-glycol. *Life Sci* 16: 273-280.
8. Meltzer H, Belmaker RH, Wyatt RJ, Pollin W and Cohen S (1976). Serum creatinine phosphokinase (CPK) activity in monozygotic twins discordant for schizophrenia. *Comprehensive Psychiatry* 17: 469-475.
9. Belmaker RH and Wyatt RJ (1976). Possible X-linkage in a family with varied psychoses. *Israel Annals of Psychiatry* 14: 345-353.
10. Grunhaus L, Ebstein RP, Belmaker RH, Sandler SC. and Jonas WS (1976). A twin study of human red blood cell catechol-O-methyltransferase. *Brit J Psychiat* 128: 494- 498.

11. Belmaker RH, Ebstein RP and Benbenisty D (1976). Electrophoretic pattern of plasma MAO in schizophrenia and affective illness. *J Psychiat Res* 13: 119-123.
Selected for digesting in Psychiatry Digest (1977)
12. Belmaker RH, Ebstein RP, Ebbesen K and Rimon R (1976). Platelet monoamine oxidase in schizophrenia and manic- depressive illness. *Brit J Psychiat* 129: 227-232.
13. Belmaker RH, Pollin W, Jenkins D and Brensiki J (1976). Coronary-prone behavior pattern in a sample of Type II hypercholesteremic patients. *J Psychosom Res* 20: 591- 594.
14. Ebstein RP, Belmaker RH, Benbenisty D and Rimon R (1976). Electrophoretic pattern of red blood cell catechol-O-methyltransferase in schizophrenia and manic-depressive illness. *Biol Psychiat* 11: 613-624.
15. Ebstein RP, Belmaker RH, Grunhaus L and Rimon R (1976). Lithium inhibition of adrenaline-sensitive adenylate cyclase in humans. *Nature* 259: 411-413.
16. Belmaker RH, Ebstein RP, Schoenfeld H and Rimon R (1976). The effect of haloperidol on epinephrine-stimulated adenylate cyclase in humans. *Psychopharmacology* 49: 215- 217.
17. Biederman J, Rimon R, Ebstein RP, Zohar J and Belmaker RH (1976). Neuroleptics reduce spinal fluid cyclic AMP in schizophrenic patients. *Neuropsychobiology* 2: 324-327.
18. Belmaker RH, Ebstein RP, Rimon R, Wyatt RJ and Murphy D (1976). Electrophoresis of platelet monoamine oxidase in schizophrenia and manic-depressive illness. *Acta Psychiat Scand* 54: 67-72.
19. Ebstein RP, Biederman J, Rimon R, Zohar J and Belmaker RH (1976). Cyclic GMP in the CSF of patients with schizophrenia before and after neuroleptic treatment. *Psychopharmacology* 51: 71-74.
20. Gershon ES, Belmaker RH, Ebstein RP and Jonas WZ (1977). Plasma monoamine oxidase activity unrelated to genetic vulnerability to primary affective illness. *Arch Gen Psychiat* 34: 731-734.
21. Rimon R, Belmaker RH and Ebstein RP (1977). Psychosomatic aspects in juvenile rheumatoid arthritis. *Scand J Rheumatology* 6: 1-10.
22. Biederman J, Rimon R, Ebstein RP, Belmaker RH and Davidson JT (1977). Cyclic AMP in the CSF of patients with schizophrenia. *Brit J Psychiat* 130: 64-671.
23. Murphy DL, Belmaker RH, Carpenter WT and Wyatt RJ (1977). Monoamine oxidase in chronic schizophrenia: Studies of hormonal and other factors affecting enzyme activity. *Brit J Pschiat* 130: 151-158.
24. Murphy DL, Belmaker RH, Buchsbaum M, Martin NF, Ciaranello R and Wyatt RJ (1977). Biogenic amine-related enzymes and personality variations in normals. *Psychol Med* 7: 149-157.

25. Ebstein RP, Kara T and Belmaker RH (1977). The effect of lithium on the glucagon-sensitive adenylate cyclase in vivo in man. *Acta Pharmacol Toxicol* 41: 80-83.
26. Feine R, Belmaker RH, Rimon R and Ebstein RP (1977). Platelet monoamine oxidase in women with premenstrual syndrome. *Neuro-psychobiology* 3: 105-110.
27. Reches A, Ebstein RP and Belmaker RH (1977). d-Amphetamine inhibition of platelet MAO in schizophrenia. *Biol Psychiat* 12: 655-660.
28. Kadouch R, Belmaker RH, Ebstein RP and Perez L (1977). The mood response and plasma cyclic AMP response to intravenous methylphenidate. *Neuropsychobiology* 3: 250-255.
29. Meltzer H, Dorus E, Grunhaus L, Davis JM and Belmaker RH (1978). Genetic control of human plasma creatinine phosphokinase activity. *Clinical Genetics* 13: 321-326.
30. Lichtstein D, Dobkin J, Ebstein RP, Biederman J, Rimon R and Belmaker RH (1978). GABA in the CSF of schizophrenic patients before and after neuroleptic treatment. *Brit J Psychiat* 132: 145-148.
31. Reches A, Ebstein RP and Belmaker RH (1978). Differential effect of lithium on noradrenaline and dopamine-sensitive accumulation of cyclic AMP in guinea pig brain. *Psychopharmacology* 58: 213-216.
32. Ebstein RP, Reches A and Belmaker RH (1978). Lithium inhibition of the adenosine-induced increase of adenylate cyclase activity. *J Pharm Pharmac* 30: 122-123.
33. Zohar J, Rimon R, Biederman J, Ebstein RP and Belmaker RH (1978). Clinical correlates of CSF cyclic nucleotides in schizophrenia. *Am J Psychiat* 135: 253-255.
34. Belmaker RH, Hattab J and Ebstein RP (1978). Plasma dopamine-beta-hydroxylase in childhood psychoses. *J Aut Child Schiz* 8: 293-298.
35. Wald D, Ebstein, RP and Belmaker RH (1978). Haloperidol and lithium blocking of the mood response to intravenous methylphenidate. *Psychopharmacology* 57: 83-87.
36. Belmaker RH, Ebstein RP, Biederman J, Stern R, Berman M and Van Praag HM (1978). The effect of L-dopa and propranolol on human CSF cyclic nucleotides. *Psychopharmacology* 58: 307-310.
37. Gagrat D, Hamilton J and Belmaker RH (1978). Intravenous diazepam in the treatment of neuroleptic-induced acute dystonia and akathisia. *Am J Psychiat* 135: 1232-1233.
38. Belmaker R.H, Lehrer R., Ebstein RP, Lettik H and Kugelmass S (1979). A possible cardiovascular effect of lithium. *Am J Psychiat* 136: 577-579.

39. Biederman J, Lerner Y and Belmaker RH (1979). Combination of lithium carbonate and haloperidol in schizoaffective disorder: a controlled study. *Arch Gen Psychiat*.36: 327-333.
40. Belmaker RH, Ebstein RP, Dasberg H, Levy A, Sedvall G and van Praag HM (1979). The effect of propranolol treatment in schizophrenia on CSF amine metabolites and prolactin. *Psychopharmacology* 63: 293-296.
41. Ebstein RP, Pickholz D and Belmaker RH (1979). Dopamine receptor changes after long-term haloperidol treatment in rats. *J Pharm Pharmac* 31: 558-559.
42. Oppenheim G, Ebstein RP and Belmaker RH (1979). The effect of lithium on physostigmine-induced behavioral syndrome and plasma cyclic GMP. *J Psychiat Res* 15: 133-138.
43. Lerner Y, Lwow E, Levitin A and Belmaker RH (1979). Acute high dose parenteral haloperidol treatment of psychosis. *Am J Psychiat* 136: 1061-1064.
44. Belmaker RH and Ebstein RP (1979). Biological research in psychosis (in Hebrew). *Harefuah: J Israel Med Assoc* 96: 491-493.
45. Biederman J, Lerner Y and Belmaker RH (1979). Diagnostic issues in mania (in Hebrew). *Harefuah: J Israel Med Assoc* 97: 28-29, 1979.
46. Ebstein RP, Pickholz D, Sternberg S, Strajelevich D and Belmaker RH (1979). Chronic high-dose propranolol does not increase dopamine receptor number. *J Pharm Pharmacol* 31: 860-861.
47. Belmaker RH, Kon M, Ebstein RP and Dasberg H (1980). Partial inhibition by lithium of the epinephrine-stimulated rise in plasma cyclic GMP in humans. *Biol Psychiat* 15: 3-8.
48. Hermoni M, Lerer B, Ebstein RP and Belmaker RH (1980). Chronic lithium prevents reserpine-induced supersensitivity of adenylate cyclase. *J Pharm Pharmacol* 32: 510-511.
49. Ebstein RP, Eliashar S, Ben Uriah Y, Yehuda S and Belmaker RH (1980). Chronic lithium treatment and dopamine mediated behavior. *Biol Psychiat* 15: 459-467.
50. Ebstein RP, Hermoni M and Belmaker RH (1980). The effect of lithium on noradrenaline-induced cyclic AMP accumulation in rat brain: Inhibition after chronic treatment and absence of super-sensitivity. *J Pharm Exp Ther* 213: 161-167.
51. Belmaker RH, Bracha H and Ebstein RP (1980). Platelet MAO in affective illness and alcoholism. *Schizophrenia Bulletin* 6: 320-323. Citations: 41
52. Lerer B, Birmacher B, Ebstein RP and Belmaker RH (1980). Forty-eight hour depressive cycling induced by antidepressant. *Brit J Psychiat* 137: 183-185.
53. Bannet J, Belmaker RH and Ebstein RP (1980). The effect of drug holidays in an animal model of tardive dyskinesia. *Psychopharmacology* 69: 223-224.

54. Bannet J, Gillis S, Ebstein RP and Belmaker RH (1980). The effect of chronic sulpiride on striatal spiperone binding. *Int Pharmacopsychiat* 15: 334-337.
55. Lerer B, Ebstein RP, Felix A and Belmaker RH (1980). Lithium amelioration of reserpine-induced hypoactivity in rats. *Int Pharmacopsychiat* 15: 338-343.
56. Bannet J, Lerer B, Ebstein RP, Ben-David M and Belmaker RH (1981). Lack of effect of beta-2 adrenergic stimulation on human prolactin. *Psychoneuroendocrinology* 6: 177-179.
57. Belmaker RH, Bannet J, Brecher-Fride E, Yanai Y and Ebstein RP (1981). The effect of haloperidol feeding on dopamine receptor number in ten mouse strains. *Clinical Genetics* 19: 353-357.
58. Bannet, J, Belmaker RH and Ebstein RP (1981). Individual differences in the response of DA receptor number to chronic haloperidol treatment. *Biol Psychiat*.16: 1059-1065.
59. Lerer B, Ebstein RP and Belmaker RH (1981). Subsensitivity of human beta-adrenergic adenylate cyclase after salbutamol treatment of depression. *Psychopharmacology* 75: 169-172.
60. Kobrin I, Ebstein RP, Belmaker RH and Ben-Ishai D (1981). Cyclic AMP generation in medulla oblongata and hypothalamus of hypertension-prone and resistant rats. *J Neurochem* 36: 1285-1288.
61. Goldman Z, Ebstein RP, Lerer B, Zohar J, Hermoni M and Belmaker RH (1981). Haloperidol blood levels during dosage reduction in chronic schizophrenic patients. *Neuropsychobiology* 7: 281-284.
62. Belmaker RH (1981). Receptors, adenylate cyclase, depression and lithium. *Biol Psychiat* 16: 333-350.
1980 AE Bennett Award Paper
63. Rimon R, Averbuch I, Rozick P, Fijman-Danilovich L, Kara T, Dasberg H, Ebstein RP and Belmaker RH (1981). Serum and CSF levels of haloperidol by radioimmunoassay and radioreceptor assay during high-dose therapy of resistant schizophrenic patients. *Psychopharmacology* 73: 197-199.
64. Globus M, Lerer B, Hamburger R and Belmaker RH (1981). Chronic ECT and chronic haloperidol administration are not additive in effects on DA receptors. *Neuropharmacology* 20: 1125-1128.
65. Lerer B, Jabotinsky-Rubin K and Belmaker RH (1981). Electro-convulsive therapy - its biological mechanisms (in Hebrew). *Harefuah: J Israel Med Assoc* 101: 221-223.
66. Apter A, Weizman A, Weizman R, Tyano S and Belmaker RH (1981). Minimal brain dysfunction - A critical review (in Hebrew) *Harefuah: J Israel Med Assoc* 101: 366-367.

67. Belmaker RH, Lerer B, Bannet J and Birmaher B (1981). The effect of electroconvulsive shock at a clinically equivalent schedule on rat cortical beta-adrenoreceptors. *J Pharm Pharmacol* 34: 275.
68. Eisenberg J, Brecher-Fride E, Weizman R, Ebstein RP and Belmaker RH (1982). Dopamine receptors in a rat model of MBD. *Neuropsychobiology* 8: 151-155.
69. Zohar J, Spiro D, Novack A, Ebstein RP and Belmaker RH (1982). Lack of benefit from magnesium in lithium toxicity. *Neuropsychobiology* 8: 10-11.
70. Lerer B, Jabotinsky-Rubin K, Bannet J, Ebstein RP. and Belmaker RH (1982). Electroconvulsive therapy prevents dopamine receptor supersensitivity. *Eur J Pharmacol* 80: 131-134, 1982.
71. Zohar J, Lerer B, Ebstein RP and Belmaker RH (1982). Lithium does not prevent agonist-induced subsensitivity of human adenylate cyclase. *Biol Psychiat* 17: 343-350.
72. Lerer B and Belmaker RH. Receptors and the mechanism of action of ECT (1982). *Biol Psychiat* 17: 497-511.
73. Bannet J, Ebstein RP, Herskowitz M and Belmaker RH (1982). Chronic rubidium does not prevent dopamine receptor super-sensitivity. *Neuropsychobiology* 8: 281-283.
74. Lerer B, Birmaher B and Belmaker RH (1982). Electroconvulsive therapy - its place in psychiatric treatment (in Hebrew). *The Family Physician* 11: 75-80.
75. Birmaher B, Lerer B and Belmaker RH (1982). Lithium does not prevent ECS-induced decreases in beta-adrenergic receptors. *Psychopharmacology* 78: 190-192.
76. Globus, M, Bannet J, Lerer B and Belmaker RH (1982). The effect of chronic bromocriptine and L-dopa on spiperone binding and apomorphine-induced stereotypy. *Psychopharmacology* 78: 81-84.
77. Levy A, Zohar J and Belmaker RH (1982). The effect of chronic lithium pretreatment on rat brain muscarinic receptor regulation. *Neuropharmacology* 21: 1199-1201.
78. Bannet J, Gologorsky-Chazan S and Belmaker RH (1983). Memory impairment and ventricular enlargement in a subgroup of schizophrenics (in Hebrew). *Harefuah: J Israel Med Assoc* 104: 460-462.
79. Zohar J, Bannet J, Drummer D, Fisch R, Ebstein RP and Belmaker RH (1983). The response of lymphocyte beta- adrenergic receptors to chronic propranolol treatment in depressed patients, schizophrenic patients and normal controls. *Biol Psychiat* 18: 553-560.
80. Fisch RC, Bannet J and Belmaker RH (1983). The function of noradrenaline in schizophrenia (in Hebrew). *Harefuah: J Israel Med Assoc* 104: 398-401.

81. Goldin L, Gershon E and Belmaker RH (1983). HLA and affective disorders (in Hebrew). Editorial, *Harefuah: J Israel Med Assoc* 105: 234.
82. Rimon R, Terenius L, Averbuch I and Belmaker RH (1983). High-dose haloperidol increases CSF opioid activity in patients with chronic schizophrenia. *Pharmacopsychiatry* 16: 9-12.
83. Ebstein RP, Lerer B, Shlaufman M and Belmaker RH (1983). The effect of repeated electroconvulsive treatment and chronic lithium feeding on the release of norepinephrine from rat cortical vesicular preparations. *J Cell Molec Neurobiol* 3: 191-201.
84. Newman M, Klein E, Birmaher B, Feinsod M and Belmaker RH (1983). Lithium at therapeutic concentrations inhibits human brain noradrenaline-sensitive cyclic AMP accumulation. *Brain Research* 278: 380-381.
85. Lerer B and Belmaker RH (1983). Electroconvulsive therapy in our times (in Hebrew). Editorial. *Harefuah: J Israel Med Assoc* 105: 431-432.
86. Lerer B, Zabow T, Egnoll N and Belmaker RH (1983). Effect of vasopressin on memory following ECT. *Biol Psychiat* 18: 821-824.
87. Belmaker RH, Lerer B, Klein E, Newman M and Dick E (1983). Clinical implications of research on the mechanism of action of lithium. *Progress in Neuropsychopharmacology and Biological Psychiatry* 7: 287-296.
88. Lerer B, Globus M, Brik E, Hamburger R and Belmaker RH (1984). Effect of treatment and withdrawal from chronic lithium in rats on stimulant-induced responses. *Neuropsychobiology* 11: 28-32.
89. Klein E, Bental E, Lerer B and Belmaker RH (1984). Carbamazepine and haloperidol versus placebo and haloperidol in excited psychoses: A controlled study. *Arch Gen Psychiat* 41: 165-170. Citations: 136
Selected for Psychiatry Digest April, 1984.
90. Weizman A, Weitzman R, Szekely A, Tyano S and Belmaker RH (1984). Combination of neuroleptic and stimulant treatment in attention deficit disorder with hyperactivity. *J Am Child Psychiat* 23: 295-298.
91. Klein E, Lerer B, Newman M, Belmaker RH and Bhargava HN (1984). The effect of cyclo (Leu-Gly) on reserpine- induced hypomotility and increases in cortical beta- adrenergic receptors. *Psychopharmacology* 83: 76-78.
92. Newman M, Zohar J, Kalian and Belmaker RH (1984). The effects of chronic lithium and ECT on A₁ and A₂ adenosine receptor systems in rat brain. *Brain Research* 291: 188-192.
93. Belmaker RH (1984). Adenylate cyclase and the search for new compounds with the clinical profile of lithium. *Pharmacopsychiatry* 17: 9-15.
1983 Anna Monika Prize

94. Hamburger-Bar R, Ebstein RP and Belmaker RH (1984). Vasopressin effect on learning in 6-OH DA pretreated rats: Correlation with caudate vasopressin levels. *Biol Psychiat* 19: 735-743.
95. Belmaker RH, Zohar J, Rimon R and Averbuch I (1984). Cyclic AMP and GMP in the CSF after high-dose haloperidol treatment. *Polish J Pharmacol Pharmac* 36: 217-220.
96. Belmaker RH (1984). The lessons of platelet monoamine oxidase. (editorial) *Psychol Med* 14: 249-253.
97. Zohar J and Belmaker RH (1984). Clinical correlates of neuroleptic blood levels (in Hebrew). *Harefuah: J Israel Med Assoc* 106: 77-81.
98. Belmaker RH, Stein D, Eisenberg J and Hamburger-Bar R (1984). Clinical studies of in learning disorders. *Clinical Neuropharmacology* 7: (Suppl) 742-743.
99. Goldberg M, Hattab J, Meir D, Ebstein RP and Belmaker RH (1984). Plasma cyclic AMP and cyclic GMP in childhood-onset psychoses. *J Aut Dev Dis* 14: 159-164.
Selected for digesting in Digest of Psychiatry and Neurology, Aug. 1984.
100. Mandel B, Last U, Belmaker RH and Rosenbaum M (1984). Rorschach markers in euthymic manic-depressive illness. *Neuropsychobiology* 12: 96-100.
101. Klein E, Belmaker RH, Newman M and Gruskiewicz J (1984). A comparison of lithium effects on human brain and rat brain noradrenaline-sensitive adenylate cyclase. *Acta Pharmacol Toxicol Scand* 56: 15-20.
102. Eisenberg J, Hamburger-Bar R and Belmaker RH (1984). The effect of vasopressin treatment on learning in Down's syndrome. *J Neural Trans* 60: 143-147.
103. Eisenberg J, Gologorsky-Chazan S, Hattab J and Belmaker RH (1984). A controlled trial of vasopressin treatment of childhood learning disorder. *Biol Psychiat* 19: 1137- 1141.
104. Stein D, Bannet J, Averbuch I, Landa L, Gologorsky-Chazan S and Belmaker RH (1984). Ineffectiveness of vasopressin in the treatment of memory impairment in chronic schizophrenia. *Psychopharmacology* 84: 566-568.
105. Klein E and Belmaker RH (1984). The place of carbamazepine in the treatment of manic-depressive illness (in Hebrew) *Harefuah: J Isr Med Assoc* 107:176-180.
106. Lichtshtein D, Minc D, Bourrit A, Deutsch J, Karlish SJD, Belmaker RH, Rimon R and Palo J (1985). Evidence for the presence of 'ouabain like' compound in human cerebrospinal fluid. *Brain Research* 325: 13-19.
107. Hamburger-Bar R, Klein A and Belmaker RH (1985). The effect of chronic vs acute injection of vasopressin on animal learning and memory. *Peptides* 6: 23-25.
108. Kidron R, Averbuch I, Klein E and Belmaker RH (1985). Carbamazepine-induced reduction of blood levels of haloperidol in chronic schizophrenia. *Biol Psychiat* 20: 219-222.

- Zohar J, Drummer D, Edelstein E, Kaizer N, Belmaker RH and Nir Y (1985). Effect of lysine vasopressin in depressed patients on mood and 24 hour rhythm of growth hormone, cortisol, melatonin and prolactin. *Psychoneuroendocrinology* 10: 273-279.
109. Greenberg D and Belmaker RH (1985). DDAVP as a possible method to enhance positive benefit of behavior therapy. *Brit J Psychiat* 147: 713-715.
110. Newman ME, Lichtenberg P and Belmaker RH (1985). Effects of lithium in vitro on noradrenaline-induced cyclic AMP accumulation in rat cortical slices after reserpine-induced supersensitivity. *Neuropharmacol* 24: 353-355.
111. Shapira B, Zohar J, Newman M, Drexler H and Belmaker RH (1985). Potentiation of seizure length and clinical response to ECT by caffeine pretreatment. A case report. *Convulsive Therapy* 1: 58-60.
112. Shapira B, Oppenheim G, Zohar J, Segal M, Malach D and Belmaker RH (1985). Lack of efficacy of estrogen supplementation to imipramine in resistant female depressives. *Biol Psychiat* 20: 570-583.
113. Stein D, Baron M, Avni Y, Gilboa P and Belmaker RH (1985). The X-linkage hypothesis of the inheritance of manic- depressive illness. (in Hebrew) *Harefuah: J Isr Med Assoc* 109: 25-30.
114. Zohar J, Shapira B, Oppenheim G, Ayd FJ and Belmaker RH (1985). Addition of estrogen to imipramine in female resistant depressives. *Psychopharmacol Bull* 21: 705-706.
115. Hamburger R, Sela A, and Belmaker RH (1985). Differences in learning and extinction in response to vasopressin in six inbred mouse strains. *Psychopharmacol* 87: 124-125.
116. Zohar J, Birmaher B, Schoenfeld H and Belmaker RH (1986). Salivary and blood levels of neuroleptics during outpatient maintenance treatment. *Isr J Psychiat Rel Sci* 23: 123- 128.
117. Hamburger-Bar R, Robert M, Newman M and Belmaker RH (1986). Interstrain correlation between behavioral effects of lithium and effects on cortical cyclic AMP. *Pharmacol Biochem Behav* 24: 9-13.
118. Belmaker RH, Dagan A and Bleich A (1986). Enuresis nocturna in young adults (in Hebrew) *Harefuah: J Isr Med Assoc* 111: 181-185.
119. Chazan S, Bannet J, Gutman R and Belmaker RH (1986). Familial correlation of memory function in schizophrenia. *Psychopathology* 19: 165-169.
120. Belmaker RH and Bleich A (1986). Use of desmopressin in adult enuresis. *Military Medicine* 151: 660-662.
121. Zohar J, Shemesh Z and Belmaker RH (1986). Utility of feedback of neuroleptic blood levels in the treatment of acute psychosis. *J Clin Psychiat* 47: 600-603.

122. Newman M and Belmaker RH (1987). Effect of lithium in vitro and ex vivo on components of the adenylate cyclase system in rat cerebral cortex membrane. *Neuropharmacol* 26: 211- 217.
123. Hamburger-Bar R, Eisenberg J, and Belmaker RH (1987). Animal and clinical studies of vasopressin effects on learning and memory. *Isr J Med Sci* 23: 12-18.
124. Baron M, Risch N, Hamburger R, Mandel B, Kushner S, Newman M, Drumer D and Belmaker RH (1987). Genetic linkage between X-chromosome markers and bipolar affective illness. *Nature* 326: 289-292. Citations:
125. Schreiber G and Belmaker, RH (1987). In vivo differentiation of cardiac vagal blocking effects of chlorpromazine and haloperidol using respiratory sinus arrhythmia measurements. *Biol Psychiat* 22: 1417-1421.
126. Avissar S, Schreiber G, Danon A and Belmaker RH (1988). Lithium inhibits adrenergic and cholinergic increases in GTP binding in rat cortex. *Nature* 331: 440-442.
127. Kaplan Z, Schreiber G and Belmaker RH (1988). Lack of effectiveness of forskolin or inositol as antidote in lithium toxicity. *J Neuro Transmiss* 72: 167-170.
128. Last U, Mandel B, Shapiro E and Belmaker RH (1989). In search of psychological markers of bipolar manic-depressive illness (BMDI): Some commonalities in psychological functioning between offspring of BMDI-affected parents and adult euthymic BMDI patients. *Isr J Psychiat Rel Sci* 26: 75-84.
129. Moscovich D, Belmaker RH, Agam G and Livne A (1990). Inositol-1-phosphatase in RBC of manic-depressive patients before and during treatment with lithium. *Biol Psychiat* 27: 552-555.
130. Kofman O, Belmaker RH (1990). Intracerebroventricular myo- inositol antagonizes lithium-induced suppression of rearing behaviour in rats. *Brain Research* 534: 345-347.
131. Kofman O, Klein E, Newman M, Hamburger R, Kimche O, Nir T, Shimon H and Belmaker RH (1990). Inhibition by antibiotic tetracyclines of rat cortical noradrenergic adenylate cyclase and amphetamine-induced hyperactivity. *Pharmacology, Biochemistry & Behaviour* 37: 417-424.
132. Givant Y, Zohar J, Lichtenberg P, Kofman O and Belmaker RH (1990). Chronic lithium attenuates clenbuterol- induced hypoactivity. *Lithium* 1: 183-185.
133. Belmaker RH and Kofman O (1990). Lithium research: state of the art. (editorial) *Biological Psychiatry* 27: 1279-1281.
134. Baron M, Hamburger R, Sandkuyl L, Risch N, Mandel B, Endicott J, Kushner S, Newman M, Belmaker RH, Ott J (1990). The impact of phenotypic variation on genetic analysis: application to X-linkage in manic-depressive illness. *Acta Psychiatrica Scandinavica* 82: 196-203.
135. Belmaker RH, Lerer B, Newman M and Fuchs I (1991). Lack of effect of lithium, propranolol or haloperidol on basal plasma cyclic AMP levels. *Lithium* 2: 115-121.

136. Schreiber G, Avissar S, Danon A and Belmaker RH (1991). Hyperfunctional G proteins in lymphocytes of patients with mania. *Biological Psychiatry* 29: 273-280.
137. Belmaker RH (1991). One gene per psychosis? (editorial) *Biological Psychiatry* 29: 415-417.
138. Fux M, Belmaker RH (1991). A controlled comparative study of chlorprothixene vs. haloperidol in chronic schizophrenia. *Isr J Psychiatry Rel Sci* 28: 37-40.
139. Kofman O, Belmaker RH, Grisaru N, Alpert C, Fuchs I, Katz V, Rigler O (1991). Myo-inositol attenuates two specific behavioral effects of acute lithium in rats. *Psychopharmacology Bulletin* 27: 185-190.
140. Asali A, Khamaysi N, Aburabia Y, Belmaker RH (1992). Female circumcision. *Harefuah: J Isr Med Assoc* 122: 461-464 (in Hebrew).
141. Zilberman-Kaufman M, Agam G, Moscovitz L, Livne AA, Belmaker RH (1992). Raised monophosphatase activity in schizophrenic patients. *Clinica Chemica Acta* 209: 89-93.
142. Benjamin J, Belmaker RH, Bersudsky Y, Revasov A, Kofman O (1992). Failure of addition of lithium to imipramine to enhance activity in rats or mood in normal volunteers. *Pharmacology and Toxicology* 71: 18-25.
143. Moscovich DG, Shapira B, Lerer B and Belmaker RH (1992). Rapid lithiumization in acute manic patients. *Human Psychopharmacology* 7: 343-345.
144. Bersudsky Y, Vinnitsky I, Grisaru N, Yaroslavsky U, Gheorghiu, Ivgi D, Kofman O and Belmaker RH (1992). The effect of inositol on lithium - induced polyuria-polydipsia in rats and humans. *Human Psychopharmacology* 7: 403-407.
145. Kofman O, Sherman WR, Katz V, Belmaker RH (1993). Restoration of brain myo-inositol levels in rats increases latency to lithium-pilocarpine seizures. *Psychopharmacology* 110: 229-234.
146. Levine J, Umansky R, Ezrielev G, Belmaker RH (1993). Lack of effect of inositol treatment in chronic schizophrenia. *Biological Psychiatry* 33: 673-675.
147. Grisaru N, Paronsky A, Zabow, A Belmaker RH (1993). The effect of life-threatening war stress on an acute psychiatric ward. *Stress Medicine* 9: 141-143.
148. Levine J, Gonzalves M, Barbam I, Stier S, Elizur A, Kofman O, Belmaker RH (1993). Inositol 6 gm daily may be effective in depression but not in schizophrenia. *Human Psychopharmacology* 8: 49-53.
149. Kofman O, Bersudsky Y, Vinnitsky I, Alpert C and Belmaker RH (1993). The effect of peripheral inositol injection on rat motor activity models of depression. *Israel Journal of Medical Sciences* 29: 580-586.
150. Benjamin J, Press J, Maoz B, Belmaker RH (1993). Linkage of a normal personality trait to the color-blindness gene: preliminary evidence. *Biological Psychiatry* 34: 581-583.

151. Levine J, Rapaport A, Lev L, Bersudsky Y, Kofman O, Belmaker RH, Shapiro J and Agam G (1993). Inositol treatment raises CSF inositol levels. *Brain Research* 627: 168-170.
152. Agam G, Shapiro J, Levine J, Stier S, Schields C, Bersudsky Y and Belmaker RH (1993). Short-term lithium treatment does not reduce human CSF inositol levels. *Lithium* 4: 267-269.
153. Kofman O and Belmaker RH (1993). Biochemical, behavioral and clinical studies of the role of inositol in lithium treatment and depression. *Biological Psychiatry* 34: 839-852.
(Ziskind-Somerfeld Research Award Paper)
154. Bersudsky Y, Vinnitsky I, Ghelber D, Kofman O, Kaplan Z and Belmaker RH (1993). Mechanism of lithium lethality in rats. *Journal of Psychiatric Research* 27: 415-422.
155. Belmaker and Biederman J (1994). Genetic markers, temperament and psychopathology (editorial). *Biological Psychiatry* 36: 71-72.
156. Agam G, Shapiro J, Bersudsky Y, Kofman O and Belmaker RH (1994). High-dose peripheral inositol raises brain inositol levels and reverses behavioral effects of inositol depletion by lithium. *Pharmacology, Biochemistry & Behavior* 49: 341-343.
157. Bersudsky Y, J Shapiro, Agam G, Kofman O and Belmaker RH (1994). Behavioral evidence for the existence of two pools of cellular inositol. *European Neuropsychopharmacology* 4: 463-467.
158. Levine J, Goldberger I, Rapaport A, Schwartz M, Schields C, Elizur A, Belmaker RH, Shapiro J, Agam G (1994). CSF inositol levels in schizophrenia are unchanged and inositol is not therapeutic in anergic schizophrenia. *European Neuropsychopharmacology* 4: 487-490.
159. Asali A, Khamaysi N, Aburabia Y, Letzer S, Halihal B, Sidovsky M, Maoz B and Belmaker RH (1995). Ritual female genital surgery among Bedouin in Israel. *Archives of Sexual Behavior* 24: 573-577.
160. Levine J, Barak Y, Gonsalves M, Szor H, Elizur A, Kofman O and Belmaker RH (1995). A double-blind controlled trial of inositol treatment of depression. *American Journal of Psychiatry* 152: 792-794.
161. Manji HK, Chen G, Shimon H, Hsiao JK, Potter WZ, Belmaker RH (1995). Guanine nucleotide-binding in bipolar affective disorder: the effect of long term lithium treatment. *Archives of General Psychiatry* 52: 135-144.
162. Levine J, Barak Y, Kofman O and Belmaker RH (1995). Follow-up and relapse analysis of an inositol study of depression. *Israel Journal of Psychiatry* 32: 14-21.
163. Alexander JR, Benjamin J, Lerer B, Baron M, Belmaker RH (1995). Frequency of positive family history in bipolar patients in catchment-area population. *Progress in Neuropsychopharmacol & Biol Psychiat* 19: 367-373.

164. Benjamin J, Levine J, Fux M, Aviv A, Levy D and Belmaker RH (1995). Inositol treatment for panic disorder: a double-blind placebo-controlled crossover trial. *American Journal of Psychiatry* 152: 1084-1086.
165. Agam G, Belfair N, Shapiro J, Shimon H, Belmaker RH (1995). Plasma inositol levels in lithium-treated manic-depressives, schizophrenics and controls. *Human Psychopharmacology* 10: 311-314.
166. Fleischmann A, Prolov K, Abarbanel J, Belmaker RH (1995). The effect of transcranial magnetic stimulation of rat brain on behavioral models of depression. *Brain Research* 699: 130-132.
167. Belmaker RH and Fleischmann A (1995). Transcranial Magnetic Stimulation: a potential new frontier in psychiatry. *Biological Psychiatry* 38: 419-421.(editorial).
168. Levine J, Ring A, Barak Y, Elizur A and Belmaker RH (1995). Inositol may worsen attention deficit disorder with hyperactivity. *Human Psychopharmacology* 10: 481-484. Citations: 19
169. Levine J, Pomerantz T, Stier S, Belmaker RH (1995). Lack of effect of 6 gm inositol treatment on post-ECT cognitive function in humans. *J Psychiatric Research* 29: 487-489.
170. Ebstein R, Novick O, Umansky R, Priel B, Osher Y, Blaine D, Nemanov L, Katz M, Bennett E and Belmaker RH (1996). Dopamine D4 receptor (D4DR) exon III polymorphism associated with human personality trait of Novelty Seeking. *Nature Genetics* 12: 78-80.
171. Patishi Y, Bersudsky Y, Belmaker RH (1996). Phorbol ester intracerebroventricularly induces a behavioral hypoactivity that is not affected by chronic or acute lithium. *European Neuropsychopharmacology* 6: 39-41.
172. Patishi Y, Lubrich B, Berger M, van Calker D, Kofman O, Belmaker RH (1996). Differential uptake of myo-inositol in vivo into rat brain areas. *European Neuropsychopharmacology* 6: 73-75.
173. Abarbanel JM, Lemberg T, Yaroslavsky U, Grisaru N and Belmaker RH (1996). Electrophysiological responses to transcranial magnetic stimulation in depression and schizophrenia. *Biological Psychiatry* 40: 148-150.
174. Patishi Y, Agam G, Tardov M, Kofman O, Belmaker RH (1996). Lack of effect of ECS on rat brain inositol monophosphatase activity and cortical inositol levels and of icv inositol on ictal and postictal length. *J Psychiatric Research* 30: 39-43.
175. Patishi Y, Belmaker RH, Bersudsky Y, Kofman O (1996). A comparison of the ability of myo-inositol and epi-inositol to attenuate lithium-pilocarpine seizures in rats. *Biological Psychiatry* 39: 829-832.
176. Barak Y, Levine J, Glasman A, Elizur A, Belmaker RH (1996). Inositol treatment of Alzheimer's disease. *Progress in Neuropsychopharmacology and Biological Psychiatry* 20: 729-735.

177. Fux M, Levine J, Aviv A, Belmaker RH (1996). Inositol treatment of obsessive-compulsive disorder. *American Journal of Psychiatry* 153: 1219-1221.
178. Patishi Y, Belmaker RH and Agam G (1996). Effect of age, sex, steroids, brain region and genetic strain on brain inositol monophosphatase activity. *Biological Psychiatry* 40: 656-659.
179. Manji HK, Bersudsky B, Chen G, Belmaker RH, Potter WZ (1996). Modulation of protein kinase C isozymes and substrates by lithium: the role of myo-inositol. *Neuropsychopharmacology* 15: 370-381.
180. Osher Y, Cloninger CR and Belmaker RH (1996). Tridimensional Personality Questionnaire in euthymic manic depressive patients. *J of Psychiatric Research* 30: 353-357.
181. Grisaru N, Letzer L, Belmaker RH (1997). Female genital mutilation among Ethiopian Jews. *Archives of Sexual Behavior* 26: 211-215.
182. Fleischmann A, Sternheim A, Etgen AM, Li C, Grisaru N, Belmaker RH (1996). Transcranial magnetic stimulation downregulates β -adrenoreceptors in rat cortex. *Journal of Neural Transmission* 103: 1361-1366.
183. Richards MH, Belmaker RH (1996). Epi-inositol is biochemically active in reversing lithium effects on cytidine monophosphorylphosphatidate (CMP-PA). *Journal of Neural Transmission* 103: 1281-1285.
184. Levine J, Kurtzman L, Rapoport A, Zimmerman J, Bersudsky Y, Shapiro J, Belmaker RH and Agam G (1996). CSF inositol does not predict antidepressant response to inositol. *Journal of Neural Transmission* 103: 1457-1462.
185. Bersudsky Y, Kotler M, Shafrin M, Belmaker RH (1996). A preliminary study of possible psychoactive effects of intravenous forskolin in depressed and schizophrenic patients. *Journal of Neural Transmission* 103: 1463-1467.
186. Ebstein RP, Macciardi F, Heresco-Levi U, Serretti A, Blaine D, Verga M, Nemanov L, Gur E, Belmaker RH, Avnon M, Lerer B (1997). Evidence for an association between dopamine D3 receptor gene DRD3 and schizophrenia. *Human Heredity* 47: 6-16.
187. Ram A, Guedj F, Weinstein L, Grisaru N, Belmaker RH, Gershon ES, Gejman PV (1997). No abnormality in the gene for the G protein stimulatory α subunit in patients with bipolar disorder. *Archives of General Psychiatry* 54: 44-48.
188. Geller V, Grisaru N, Abarbanel JM, Lemberg T, Belmaker RH (1997). Slow magnetic stimulation of prefrontal cortex in depression and schizophrenia. *Progress in Neuropsychopharmacol and Biol Psychiatry* 21: 105-110.
189. Ebstein R, Segman, Benjamin J, Osher Y, Nemanov B, Belmaker RH (1997). 5-HT_{2C} serotonin receptor gene polymorphism associated with human personality trait of reward dependence: interactions with D4DR and D3DR polymorphisms. *Am J Medical Genetics* 74: 65-72.

190. Ebstein RP, Gritschko I, Nemanov L, Frisch A, Osher Y, Belmaker RH (1997). No association between the serotonin transporter gene regulatory region polymorphism and the Tridimensional Personality Questionnaire (TPQ) treatment of harm avoidance. *Molecular Psychiatry* 2: 224-226.
191. Ben-Shachar D, Belmaker RH, Grisaru N, Klein E (1997). Transcranial magnetic stimulation induces alterations in brain monoamines. *Journal of Neural Transmission* 104: 191-197.
192. Cohen H, Kotler M, Kaplan Z, Matar MA, Kofman O, Belmaker RH (1997). Inositol administration has centrally-mediated behavioral effects with adaptation after chronic administration. *Journal of Neural Transmission* 104: 299-305.
193. Levine J, Aviram A, Holan A, Ring A, Barak Y, and Belmaker RH (1997). Myo-inositol treatment of infantile autism: a double-blind placebo controlled trial. *Journal of Neural Transmission* 104: 307-310.
194. Shimon H, Agam G, Belmaker RH, Hyde T, Kleinman JE (1997). Reduced frontal cortex levels in postmortem brain of suicide victims and patients with bipolar disorder. *Am J Psychiatry* 154: 1148-1150.
195. Ebstein RP, Belmaker RH (1997). Saga of an adventure gene: novelty seeking, substance abuse and the dopamine D4 receptor (D4DR) exon III repeat polymorphism (Editorial). *Molecular Psychiatry* 2: 381-384.
196. Lubrich B, Patishi Y, Kofman O, Agam G, Berger M, Belmaker RH, van Calker D (1997). Lithium-induced inositol depletion in rat brain after chronic treatment is restricted to the hypothalamus. *Molecular Psychiatry* 2: 407-412.
197. Bersudsky Y, Patishi Y, Jensen JB, Mørk A, Belmaker RH (1997). The effect of acute and chronic lithium on forskolin-induced reduction of rat activity. *Journal Neural Transmission* 104: 943-952.
198. Benjamin J, Osher Y, Belmaker RH, Ebstein R (1997). No significant association between two dopamine receptor polymorphisms and normal temperament. *Human Psychopharmacology* 13: 11-15.
199. Ebstein RP, Nemanov L, Klotz I, Gritsenko I, Belmaker RH (1997). Additional evidence for an association between the dopamine D4 receptor (D4DR) exon III repeat polymorphism and the human personality trait of Novelty Seeking. *Mol Psychiatry* 2: 472-477.
200. Einat H, Kofman O, Itkin O, Lewitan RJ, Belmaker RH (1998). Augmentation of lithium's behavioral effect by inositol uptake inhibitors. *J of Neural Transmission* 105: 31-38.
201. Roitman G, Levine J, Bersudsky Y, Belmaker RH (1998). An adenylate cyclase inhibitor in the treatment of excited psychosis. *Human Psychopharmacology* 13: 121-125.
202. Wolfson M, Hertz E, Belmaker RH, Hertz H (1998). Chronic treatment with lithium and pretreatment with excess inositol reduce inositol pool size in astrocytes by different mechanisms. *Brain Research* 787: 34-40.

203. Gavrilov V, Levine J, Agam G, Belmaker RH (1998). Lithium enhancement of the prolactin response to 5-hydroxytryptophan is not reversible by inositol. *Progress in Neuro Psychopharmacology & Biological Psychiatry* 22: 523-528.
204. Ebstein RP, Levine J, Geller V, Auerbach J, Gritsenko I, Belmaker RH (1998). Dopamine D4 receptor and serotonin transporter promoter in the determination of neonatal temperament: novelty seeking in two-week old infants. *Molecular Psychiatry* 3: 238-246.
205. Belmaker RH, Agam G, van Calker D, Richards MH, Kofman O (1998). Behavioral reversal of lithium effects by four inositol isomers correlates perfectly with biochemical effects on the PI cycle; depletion by chronic lithium of brain inositol is specific to hypothalamus; and inositol levels may be abnormal in post-mortem brain from bipolar patients. *Neuropsychopharmacology* 19: 220-232.
206. Einat H, Elkabaz-Shwartz Z, Cohen H, Kofman O, Belmaker RH (1998). Chronic epi-inositol is anxiolytic in the plus maze model in rats. *Int J Neuropsychopharmacol* 1: 31-34.
207. Einat H, Levine J, Grauer E, MacDonald K, Belmaker RH (1998). Effect of inositol treatment on the behavior of Rhesus monkeys: Preliminary results. *Progress in Neuro-Psychopharmacology & Biological Psychiatry* 22: 999-1005.
208. Atack JR, Levine J, Belmaker RH (1998) Cerebrospinal fluid inositol monophosphatase: elevated activity in schizophrenia and neuroleptic-treated depression. *Biological Psychiatry* 44:433-437.
209. Shimon H, Sobolev Y, Davidson M, Haroutunian B, Belmaker RH, Agam G (1998) Inositol levels are decreased in post mortem brain of schizophrenic patients. *Biological Psychiatry* 44:428-432.
210. Grisaru N, Chudakov B, Yaroslavsky Y, Belmaker RH (1998) TMS in mania: a controlled study. *Am J Psychiatry* 155:1608-1610.
211. Lokshin P, Kotler M, Kutzuk D, Belmaker RH (1998) Clotiapine: an old neuroleptic with possible clozapine-like properties. *Progress in Neuro-psychopharmacology & Biological Psychiatry* 22:1289-1293.
212. Shamir A, Ebstein RP, Nemanov L, Zohar A, Belmaker RH, Agam G (1998) Inositol monophosphatase in immortalized lymphoblastoid cell lines indicates susceptibility to bipolar disorder and response to lithium therapy. *Molecular Psychiatry* 3:481-482.
213. Lokshin P, Dorfman P, Shoshani D, Wimmer P, Dossenbach M, Belmaker RH (1998). Olanzapine treatment after clozapine induced agranulocytosis. *Human Psychopharmacology* 13:583-584.
214. Steen VM, Levlie R, Osher Y, Belmaker RH, Berle JO, Gulbrandsen AK (1998). The polymorphic inositol polyphosphate 1-phosphatase gene as a candidate for pharmacogenetic prediction of lithium responsive manic-depressive illness. *Pharmacogenetics* 8:259-268.

215. Elbedour S, Baker A, Shalhoub-Kevorkian N, Irwin M, Belmaker RH (1999). Psychological responses in family members after the Hebron massacre. *Anxiety and Depression* 9:27-31.
216. Levine J, Mishory A, Susnosky S, Martin M, Belmaker RH (1999). Combination of inositol and serotonin reuptake inhibitors in the treatment of depression. *Biological Psychiatry* 45: 270-273.
217. Nemanov L, Ebstein RP, Belmaker RH, Osher Y, Agam A (1999). Effect of bipolar disorder on lymphocyte inositol-monophosphatase mRNA levels. *Int J Neuropsychopharmacol* 2:25-29.
218. Auerbach J, Geller N, Letzer S, Shinwell E, Belmaker RH, Levine J, Ebstein RP. (1999). Dopamine D4 receptor (D4DR) and serotonin transporter promoter (5-HTTLPR) polymorphisms in the determination of temperament in two month old infants. *Molecular Psychiatry* 4:369-373.
219. Einat H, Karbovski H, Korik J, Tsalah D, Belmaker RH. (1999). Inositol reduces depressive-like behaviors in two different animal models of depression. *Psychopharmacology* 144:158-162.
220. Mishory A, Levine J, Kahana E, Belmaker RH. (1999). Inositol is not therapeutic in Parkinson's disease. *Human Psychopharmacology* 14:271-272.
221. Nemets B, Mishory A, Levine J, Belmaker RH. (1999). Inositol addition does not improve depression in SSRI treatment failures. *Journal of Neural Transmission* 106:795-798.
222. Fux M, Benjamin J, Belmaker RH. (1999). Inositol versus placebo augmentation of serotonin reuptake inhibitors in the treatment of obsessive-compulsive disorder: a double blind crossover study *International Journal of Neuropsychopharmacology* 2:193-195.
223. Einat H, Belmaker RH, Kopilov M, Klein E, Gazawi H, Ben-Shachar D (1999). Rat brain monoamines after acute and chronic myo-inositol treatment. *European Neuropsychopharmacology* 10:27-30.
224. Belmaker RH, Grisaru N. Antibipolar potential for TMS: an editorial (1999). *Bipolar Disorders* 2:71-72.
225. van Calker D, Belmaker RH. (2000). The high affinity inositol transport system – implications for the pathophysiology and treatment of bipolar disorder: An editorial. *Bipolar Disorders* 2:102-107.
226. Mishory A, Yaroslavsky Y, Bersudsky Y, Belmaker RH. (2000). Phenytoin as an antimanic anticonvulsant: a controlled study. *American Journal of Psychiatry* 157:463-465.
227. Wolfson M, Bersudsky Y, Zinger E, Simkin M, Belmaker RH, Hertz L. (2000). Chronic treatment of human astrocytoma cells with lithium, carbamazepine or valproic acid decreases inositol uptake at high inositol concentrations but increases it at low inositol concentrations. *Brain Research* 835:159-161.

228. Benjamin J, Osher Y, Kotler M, Gritsenko I, Nemanov L, Belmaker RH, Ebstein R. (2000). Association between tridimensional personality questionnaire (TPQ) traits and three functional polymorphisms: dopamine receptor D4 (DRD4) , serotonin transporter promoter region (5-HTTLPR) and catechol O-methyltransferase (COMT). *Molecular Psychiatry* 5:96-100.
229. Benjamin J, Osher Y, Lichtenberg P, Bachner-Melman R, Gritsenko I, Kotler M, Belmaker RH, Valsky V, Drendel M, Ebstein RP. (2000). An interaction between the catechol o-methyltransferase and serotonin transporter promoter region polymorphisms contributes to tridimensional personality questionnaire persistence scores in normal subjects. *Neuropsychobiology* 41:48-53.
230. Wolfson M, Einat H, Bersudsky Y, Berkin V, Belmaker RH, Hertz L. (2000). Nordidemnin potently inhibits inositol uptake in cultured astrocytes and dose-dependently augments lithium's proconvulsant effect in vivo. *Journal of Neuroscience Research* 60:116-121.
231. Kozlovsky N, Belmaker RH, Agam G.(2000). Low GSK-3b immunoreactivity in postmortem frontal cortex of schizophrenic patients. *Am Journal of Psychiatry* 157:831-833.
232. Shapiro J, Belmaker RH, Biegon A, Seker A, Agam G. (2000). Scyllo-inositol in port-mortem brain of bipolar, unipolar and schizophrenic patients. *J of Neural Transmission* 107:603-607.
233. Osher Y, Mandel B, Shapiro E, Belmaker RH. (2000) Rorschach markers in offspring of manic-depressive patients. *Journal of Affective Disorders* 59:231-236.
234. Dossenbach M, Beuzen JN, Avnon M, Belmaker RH, Elizur A, Mark M, Munitz H, Schneidman M, Shoshani D, Kratky P, Tollefson GD. (2000). Evidence for the effectiveness of olanzapine among treatment refractory patients non-responsive and/or intolerant to clozapine. *Clin Ther* 22:1021-0134.
235. Kremer I, Rietschel M, Dobrusin M, Majaheed M, Murad I, Blanaru M, Bannoura I, Muller DJ, Schulze TG, Reshef A, Gathas S, Schwab S, Wildenauer D, Bachner-Melman R, Belmaker RH, Maier W, Ebstein RP. (2000). No association between the dopamine D3 receptor Bal I polymorphism and schizophrenia in a family-based study of a Palestinian Arab population. *American J of Medical Genetics* 96:778-780.
236. Osher Y, El-Rom R, Belmaker RH. (2000). Predominant polarity of bipolar patients in Israel. *World J of Biological Psychiatry* 1:187-189.
237. Einat H, Clenet F, Shaldevin A, Belmaker RH, Bourin M. (2001). The antidepressant activity of inositol in the forced swim test involves 5-HT₂ receptors. *Behav Brain Research* 118:77-83.
238. Shaldivin A, Kaptsan A, Belmaker RH, Einat H, Grisaru N. (2001). Transcranial magnetic stimulation in an amphetamine hyperactivity model of mania. *Bipolar Disorders* 3:30-34.
239. Gelber D, Levine J, Belmaker RH. (2001). The effect of inositol treatment on bulimia nervosa and binge eating. *International J of Eating Disorders* 29:345-348.

240. Dossenbach M, Kratky P, Schneidmann M, Grundy S, Metcalfe S, Tollefson G, Belmaker RH. (2001). Evidence for the effectiveness of olanzapine among patients non-responsive and/or intolerant to risperidone. *J Clin Psychiatry* 62:28-34.
241. Shaldubina A, Agam G, Belmaker RH (2001). The mechanism of lithium action: state of the art, ten years later. *Prog Neuro-Psychopharmacol. & Biol Psychiat* 25:855-866.
242. Dobrusin M, Corbex M, Kremer I, Murad I, Mujaheed M, Annoura I, Muller DJ, Schulze TG, Reshef A, Blanaru M, Gathas S, Rietschel M, Belmaker RH, Maier W, Ebstein RP (2001). No evidence for linkage by transmission disequilibrium test analysis of microsatellite marker D22S278 and schizophrenia in a Palestinian Arab and in a German population. *American J Medical Genetics* 105:328-331.
243. Shaltiel G, Yaroslavsky Y, Nemetz B, Nemanov L, Ebstein R, Belmaker RH, Agam G. (2001). Inositol monophosphatase activity in brain and lymphocyte-derived cell lines of bipolar patients. *World J of Biological Psychiatry* 2:95-98.
244. Kozlovsky N, Belmaker RH, Agam G. (2001). Low GSK-3b levels in frontal cortex of schizophrenic patients are brain region specific and reflected in low enzymatic activity. *Schizophrenia Research* 52:101-105.
245. Murad I, Kremer I, Dobrusin M, Muhaheed M, Bannoura I, Muller DJ, Schulze TG, Reshef A, Blanaru M, Gathas S, Tsenter V, Rietschel M, Belmaker RH, Maier W, Ebstein RP. (2001). A family-based study of the Cys23Ser 5HT2C serotonin receptor polymorphism in schizophrenia. *Am J of Medical Genetics* 105:236-238.
246. Levine J, Leventhal U, Lerner V, Belmaker RH (2001). Inositol treatment has no effect on the dexamethasone suppression test. *World Journal of Biological Psychiatry* 2:190-192.
247. Nemets B, Stahal Z, Belmaker RH (2002). Omega-3 fatty acid treatment of depressive breakthrough during unipolar maintenance. *American Journal of Psychiatry* 159:477-479.
248. Shaldubina A, Ju S, Vaden D, Ding D, Belmaker RH, Greenberg M. (2002). Epi-inositol regulates expression of the yeast INO1 gene encoding inositol 1-P synthase. *Molecular Psychiatry* 7:174-180.
249. Einat H, Belmaker RH, Zangen A, Yadid G. (2002). Chronic inositol treatment markedly increases activity levels of Flinders Sensitive Line rats in the forced swim test. *Depression and Anxiety* 15:148-151.
250. Einat H, Shaldubina A, Szechtman H, Shimon H, Belmaker RH (2002). Preliminary evaluation of oral anticonvulsant treatment in the quinpirole model of bipolar disorder. *Journal of Neural Transmission* 109:433-440.
251. Chudakov B, Ilan K, Belmaker RH, Cwikel J. (2002). The motivation and mental health of sex workers. *Journal of Sex and Marital Therapy* 28:305-315.

252. Belmaker RH, Shapiro J, Vainer E, Nemanov L, Ebstein R, Agam G (2002). Reduced inositol content in lymphocyte derived cell lines from bipolar patients. *Bipolar Disorders* 4:67-69.
253. Kozlovsky N, Belmaker RH, Agam G. (2002). GSK-3 and the neurodevelopmental hypothesis of schizophrenia. *Eur Neuropsychopharmacol* 12:13-25.
254. Shaltiel G, Kozlovsky N, Belmaker RH, Agam G. (2002). PAP phosphatase is reduced in postmortem frontal cortex of bipolar patients. *Bipolar Disorders* 4:302-306.
255. Ebstein R, P., Zohar AH, Benjamin J, Belmaker R, H. (2002) An update of molecular genetic studies of human personality traits. *Applied Bioinformatics* 1:1-2.
256. Levine J, Stahl Z, Sela BA, Gavendo S, Ruderman V, Belmaker RH (2002). Elevated homocysteine levels in young male schizophrenic patients. *American Journal of Psychiatry* 159:1790-1792.
257. Nemets B, Talesnick B, Belmaker RH, Levine J (2002). Myo-inositol has no beneficial effect on premenstrual dysphoric disorder. *World Journal of Biological Psychiatry* 3:147-149.
258. Kozlovsky N, Belmaker RH, Agam G (2002). Lack of effect of acute, subchronic, or chronic stress on glycogen synthase kinase-3b protein levels in rat frontal cortex. *Progress in Neuro-Psychopharmacology & Biological Psychiatry* 26:1309-1312.
259. Zohar A, Dina C, Rosilio N, Osher Y, Gritsenko I, Bachner-Melman R, Lena V, Benjamin J, Belmaker RH, Richard P. Ebstein RP (2003). The Tridimensional Personality Questionnaire trait of Harm Avoidance (anxiety proneness) is linked to a locus on chromosome 8p21. *American J Medical Genetics Neuropsychiatric Genetics* 117:66-69.
260. Arbelle S, Benjamin J, Golin M, Kremer I, Belmaker RH, Ebstein RP (2003). An association between elevated scores for shyness in grade school children and the long form of the serotonin transporter promoter region polymorphism. *American Journal of Psychiatry* 160:671-6.
261. Nadri C, Lipska BK, Kozlovsky N, Weinberger DR, Belmaker RH, Agam G (2003). GSK-3 β Levels and Activity in a Neurodevelopmental Rat Model of Schizophrenia. *Developmental Brain Research* 141:33-37.
262. Kaptan A, Yaroslavsky Y, Applebaum J, Belmaker RH, Grisaru N (2003). Right prefrontal TMS vs sham treatment of mania: a controlled study. *Bipolar Disorders* 5:36-39.
263. Applebaum J, Levine J, Belmaker RH (2003). Intravenous fosphenytoin in acute mania. *Journal of Clinical Psychiatry* 64:408-409.
264. Kremer I, Pinto M, Murad I, Muhaheed M, Bannoura I, Muller DJ, Schulze TG, Reshef A, Blanaru M, Gathas S, Rietschel M, Dobrusin M, Bachner-Melman R, Belmaker RH, Maier W, Ebstein RP (2003). Family-based and case-control study

- of catechol-O-methyltransferase in schizophrenia among Palestinian Arabs. *Neuropsychiatric Genetics* 119B:35-39.
265. Kozlovsky N, Nadri C, Belmaker RH, Agam G (2003). Lack of effect of mood stabilizers or neuroleptics on GSK-3 β protein levels and GSK-3 activity. *International J of Neuropsychopharmacology* 6:117-120.
266. Shamir A, Shaltiel G, Greenberg M, Belmaker RH, Agam G (2003). The effect of lithium on expression of genes for inositol biosynthetic enzymes in mouse hippocampus; a comparison with the yeast model. *Brain Res Mol Brain Res* 115:104-10.
267. Ben-Zion IZ, Chudakov B, Cwikel J, Belmaker RH (2004). Commercial sex work: psychiatric and medical aspects (in Hebrew). *Harefuah* 143:33-36.
268. Osher Y, Sela B-A, Levine J, Belmaker RH (2004). Elevated homocysteine levels in euthymic bipolar disorder patients showing functional deterioration. *Bipolar Disorders* 6:82-86.
269. Phrolov K, Applebaum J, Levine J, Miodovnick H, Belmaker RH (2004). Single dose intravenous valproate in acute mania. *Journal of Clinical Psychiatry* 65:68-70.
270. Amar S, Jones C B, Nadri C, Kozlovsky N, Belmaker RH, Agam G (2004). Genetic correlational analysis of glycogen synthase kinase-3 β and prepulse inhibition in inbred mice. *Genes, Brain & Behavior* 3:178-80.
271. Applebaum J, Shimon H, Sela B-A, Belmaker RH, Levine J. (2004) Homocysteine levels in newly admitted schizophrenic patients. *Journal of Psychiatric Research* 38:413-416.
272. Belmaker RH (2004). Invited review: Bipolar Disorder. *New England Journal of Medicine*, Medical Progress 351:476-486.
273. Kozlovsky N, Regenold WT, Levine J, Rapoport A, Belmaker RH, Agam G (2004). GSK-3 β in cerebrospinal fluid of schizophrenia patients. *Journal of Neural Transmission* 111:1093-1098.
274. Shaltiel G, Shamir A, Shapiro J, Ding D, Dalton E, Bialer M, Harwood A, Belmaker RH, Greenberg M, Agam G (2004). Valproate decreases inositol biosynthesis. *Biological Psychiatry* 56:868-874.
275. Kozlovsky N, Shanon-Weickert C, Tomaskovic-Crook E, Kleinmann JE, Belmaker RH, Agam G (2004). Reduced GSK-3 β mRNA levels in postmortem dorsolateral prefrontal cortex of schizophrenic patients. *Journal of Neural Transmission* 111:1583-1592.
276. Cwikel J, Chudakov B, Paikin M, Belmaker RH (2004). Psychosocial characteristics of trafficked female sex workers awaiting deportation. *Archives of Women's Mental Health* 7:243-249.
277. Dina C, Nemanov L, Gritsenko I, Rosolio N, Osher Y, Herescu-Levi U, Sariashvilli E, Bachner-Melman R, Zohar AH, Benjamin J, Belmaker RH, Ebstein RP (2005).

- Fine mapping of a region of chromosome 8p strengthens evidence for a QTL contributing to the individual difference in an anxiety-related personality trait, TPQ harm avoidance. *Am Journal of Medical Genetics* 132B: 104-108.
278. Levine J, Agam G, Sela BA, Garver DL, Torrey EF, Belmaker RH (2005). CSF homocysteine is not elevated in schizophrenia. *Journal of Neural Transmission* 112:297-302.
279. Shamir A, Belmaker RH, Agam G (2005). Interaction of calbindin D_{28k}, and inositol monophosphatase in human postmortem temporal cortex: possible implications for bipolar disorder. *Bipolar Disorders* 7:42-48.
280. Stahl Z, Belmaker RH, Friger M, Levine J (2005). Nutritional and life style determinants of elevated plasma homocysteine in schizophrenia patients. *European Neuropsychopharmacology* 15:291-295.
281. Nemets B, Bersudsky Y, Belmaker RH (2005). Controlled double-blind trial of phenytoin vs. fluoxetine in major depressive disorder *The Journal of Clinical Psychiatry* 66:586-590.
282. Osher Y, Bersudsky Y, Belmaker RH (2005). Omega EPA in bipolar disorder: report of an open-label study. *Journal of Clinical Psychiatry* 66: 726-9.
283. Shamir A, Shaltiel G, Belmaker RH, Agam G (2005). Postmortem Parietal Cortex TPH2 Expression is Not Altered in Schizophrenia, Unipolar Depressed and Bipolar Patients vs. Control Subjects. *Journal of Molecular Neuroscience* 26:33-38.
284. Geller V, Gorzaltsan I, Shleifer T, Belmaker RH, Bersudsky Y (2005). Clotiapine Compared with Chlorpromazine in Chronic Schizophrenia. *Schizophrenia Research* 80:343-347.
285. Kamin R, Ben Zion I, Chudakov B, Belmaker RH (2006). Sildenafil effects on sexual function in asymptomatic volunteers: a controlled study. *Journal of Sex and Marital Therapy* 32:37-42.
286. Korostishevsky M, Kremer I, Kaganovich M, Cholostoy A, Murad I, Mul M, Bannoura I, Rietschel M, Dobrusin M, Benin-Abu-Sach U, Belmaker RH, Maier W, Ebstein RP, Navon, R (2006). Transmission disequilibrium and haplotype analysis of the G72/G30 locus: suggestive linkage to schizophrenia in Palestinian Arabs living in the north of Israel. *Neuropsychiatric Genetics* 141(1):91-5.
287. Nemets H, Nemets B, Apter A, Bracha Z, Belmaker RH (2006). Omega-3 treatment of childhood depression: a controlled double-blind trial. *American Journal of Psychiatry* 163(6):1098-100.
288. Levine J, Stahl Z, Sela BA, Ruderman V, Shumaico O, Babushkin I, Osher Y, Bersudsky Y, Belmaker RH (2006). Homocysteine reducing strategies improve symptoms in chronic schizophrenic patients with hyperhomocysteinemia. *Biological Psychiatry* 60:265-269.
289. Shaldubina A, Stahl Z, Furszpan M, Regenold WT, Shapiro J, Belmaker RH, Bersudsky Y (2006). Inositol deficiency diet and lithium effects. *Bipolar Disorders* 8(2):152-9.

290. Kozlovsky N, Amar S, Belmaker RH, Agam G (2006). Psychotropic drugs affect Ser9-phosphorylated GSK-3beta protein levels in rodent frontal cortex. *Int J Neuropsychopharmacol*. 2006 Jun;9:337-42.
291. Ben Zion IZ, Tessler R, Cohen L, Lerer E, Bachner-Melman R, Gritsenko I, Nemanov L, Zohar AH, Dina C, Belmaker RH, Benjamin J and Ebstein RP (2006). Polymorphisms in the dopamine D4 receptor gene (DRD4) contribute to individual differences in human sexual behavior: desire, arousal and sexual function. *Molecular Psychiatry* 8:782-786.
292. Shaldubina A, Johanson RA, O'Brien WT, Buccafusca R, Agam G, Belmaker RH (2006). SMIT1 haploinsufficiency causes brain inositol depletion without affecting lithium-sensitive behavior. *Molecular Genetics and Metabolism* 4:384-388.
293. Osher Y, Belmaker RH, Nemets B. (2006). Clinical Trials of PUFAs in Depression: State of the Art. *World Journal of Biological Psychiatry* 7:223-30.
294. Shapira B, Nemets B, Trachtenberg, A, Belmaker RH. (2006). Phenytoin as an augmentation for SSRI failures. *Journal of Affective Disorders* 96:123-6.
295. Ivo R, Schulze TG, Schumacher J, Kesper K, Muller DJ, Kremer I, Dobrusin M, Mujahed M, Murad I, Blanaru M, Bannoura I, Reshev A, Bachner-Melman R, Ebstein R, Propping P, Belmaker RH, Maier W, Rietschel M, Nothen MM, Cichon S. (2006). No evidence for association between NOTCH4 and schizophrenia in a large family-based and case-control association analysis. *Psychiatric Genetics* 16:197-203.
296. Kaptan A, Telias D, Bersudsky Y, Belmaker RH (2006). Ethnic origin of alcoholics admitted to an Israeli treatment center. *American Journal of Drug and Alcohol Abuse* 32:549-53.
297. Bersudsky Y, Shaldubina A, Belmaker RH (2007). Lithium's Effect in Porsolt Forced Swim Test is Blood Level Dependent but not Dependent on Weight Loss. *Behavioural Pharmacology* 18:77-80.
298. Chudakov B, Ben Zion I, Belmaker RH (2007). Transdermal testosterone gel prn application for hypoactive sexual desire disorder in premenopausal women: a controlled pilot study of the effects on the Arizona Sexual Experience Scale for Females and Sexual Function Questionnaire. *Journal of Sexual Medicine* 4:204-208.
299. Belmaker RH (2007). Treatment of bipolar depression (editorial). *New England Journal of Medicine* 17:1771-1773.
300. Shaltiel G, Dalton CE, Belmaker RH, Harwood JA, Agam G (2007). Specificity of Mood Stabilizer Action on Neuronal Growth Cones. *Bipolar Disorders* 9: 281-9.
301. Nadri C, Bersudsky Y, Belmaker RH, Agam G (2007). Elevated urinary ADAM12 protein levels in lithium-treated bipolar patients. *Journal of Neural Transmission* 114:473-7.

302. Cryns K, Shamir A, Shapiro F, Daneels G, Goris I, Hansfried Van Craenendonck H, Straetemans R, Belmaker RH, Agam G, PhD, Moechars D, Steckler T (2007). Lack of lithium-like behavioral and molecular effects in *IMPA2* knockout mice. *Neuropsychopharmacology* 32:881-91.
303. Shaldubina A, Johanson R, Buccafusca R, Agam G, Belmaker RH, Berry G, Bersudsky Y (2007). Behavioral Phenotyping of Sodium-Myo-Inositol Cotransporter heterozygous Knockout Mice with Reduced Brain Inositol, *Genes Brain and Behaviour* 6:253-9.
304. Shaltiel G, Mark S, Kofman O, Belmaker RH, Agam G (2007). Effects of valproate derivatives on human brain MIP synthase activity and amphetamine induced hyperactivity. *Pharmacological Reports* 59:401-7.
305. Belmaker RH (2007). Modafinil add-on in the treatment of bipolar depression. *American Journal of Psychiatry* (editorial) 164:1143-5.
306. Amar S, Shamir A, Ovadia O, Blanaru M, Reshef A, Kremer I, Rietschel M, Schulze TG, Maier W, Belmaker RH, Ebstein R, Agam G, Mishmar (2007). Mitochondrial DNA HV lineage increases the susceptibility to schizophrenia among Israeli Arabs. *Schizophrenia Research* 94:354-8.
307. Nadri C, Belmaker RH, Agam G (2007). Oxygen restriction of neonate rats elevates neuregulin-1a isoform levels: possible relationship to schizophrenia. *Neurochemistry International* 51:447-50.
308. Shamir A, Shaltiel G, Mark S, Bersudsky Y, Belmaker RH and Agam G (2007). Human MIP synthase splice variants in bipolar disorder. *Bipolar Disorders* 9:766-71.
309. Osher Y, Bersudsky Y, Silver H, Ben-Ami S, Belmaker RH (2008). Neuropsychological correlates of homocysteine levels in euthymic bipolar patients. *J Affect Disorders* 105:229-33.
310. Cryns K, Shamir A, Levi I, Daneels G, Goris I, Delille P, Bouwknecht A, Kass S, Agam G, Belmaker RH, Bersudsky Y, Steckler T, Moechars D (2008). *IMPA1* is essential for embryonic development and lithium-like pilocarpine sensitivity. *Neuropsychopharmacology* 33:674-84.
311. Tandon R, Moller H-J, Belmaker RH, Gattaz WF, Lopez-Ibor JJ, Okasha A, Singh, BS, Stein D, Olie J-P, Fleischhacker W (2008). World psychiatric association pharmacopsychiatry section statement on comparative effectiveness of antipsychotics in the treatment of schizophrenia. *Schizophrenia Research* 100; 20-38.
312. Bersudsky Y, Shaldubina A, Agam G, Berry G, Belmaker RH. (2008). Homozygote inositol transporter knockout mice show a lithium-like phenotype. *Bipolar Disorders* 10:453-459.
313. Mann L, Shaltiel G, Belmaker RH, Heldman E, Agam G (2008). Lithium preferentially inhibits adenylyl cyclase V and VII isoforms. *International Journal of Neuropsychopharmacology* 11:533-9.

314. Bersudsky Y, Shaldubina A, Kozlovsky N, Shoham S, Woodgett JR, Agam G, Belmaker RH (2008). Glycogen Synthase Kinase-3 β Heterozygote Knockout Mice as a Model of Findings in Postmortem Schizophrenia Brain or as a Model of Behaviors Mimicking Lithium Action: Negative Results. *Behavioral Pharmacology* 10:217-24.
315. Cleary C, Linde JA, Hiscock KM, Hadas I, Belmaker RH, Agam G, Flaisher-Grinberg S, Einat H (2008). Antidepressant-like effects of rapamycin in animal models: implications for mTOR inhibition as a new target treatment of affective disorders. *Brain Research Bulletin* 76:469-73.
316. Einat H, Tian F, Belmaker RH, Frost JW (2008). Myo-inositol-1-phosphate (MIP) synthase inhibition: in-vivo study in rats *J Neural Transm* 115:55-58.
317. Kremer I, Dobrusin M, Blanaru, Reshef A, Gathas S, Mujahed M, Maier W, Rietschel M, Schulze TG, Belmaker RH (2008). Clinical characteristics of schizophrenia: Israel Bedouin compared with Palestinian Arabs in Israel & Palestine, *Neuropsychiatry and Neuropsychology* 3:3-6.
318. Bromberg A, Levine J, Nemets B, Belmaker RH, Agam G (2008). No association between global leukocyte DNA methylation and homocysteine levels in schizophrenia patients. *Schizophrenia Research* 101: 50–57.
319. Amar S, Shaltiel G, Mann L, Shamir A, Dean B, Scarr E, Bersudsky Y, Belmaker RH, Agam G (2008). Possible involvement of post-dopamine D2 receptor signalling components in the pathophysiology of schizophrenia. *Int J Neuropsychopharmacol.* 11(2):197-205.
320. Belmaker RH, Agam G (2008). Invited review: Major Depressive Disorder. *New England Journal of Medicine, Mechanisms of Disease* 385:47-60.
321. Halila S, Belmaker RH, Abu Rabia Y, Froimovici M, Applebaum J (2009). Disappearance of female genital mutilation from the Bedouin population of Southern Israel, *Journal of Sexual Medicine* 6:70-3.
322. Dankert ME, Brensinger CM, Metzger KL, Han C, González-Pinto A, Mosquera F., Gayares JG, Li C, Severus WE, Langosch JM, Tateno M, Mihai A, Johnstone EC, MacIntyre DJ, Lallart X, Lallart E, Hoefl F, Wiguna T, Farooq S, Koleva SG, Radoeva PD, Mesén A, Laprade B, Nair SRN, M. Babb SN, Adler C, Habibpoor E, Belmaker RH, Rybakowski J, Owe-Larsson B, Young A, Malhotra S, Sivakumar, Kane J, Swanson C, Rush AJ, Siegel SJ. (2009) Attitudes Towards Implantable Psychiatric Medication in a Worldwide Sample of Patients. *Schizophrenia Research* 105(1-3):279-86.
323. Dobrusin M, Weitzman D, Levine J, Kremer I, Rietschel M, Maier W, Belmaker RH (2008). The Rate of Consanguineous Marriages Among Parents of Schizophrenic Patients in the Arab Bedouin Population in Southern Israel, *World Journal of Biological Psychiatry*, Feb 11:1-3. [Epub ahead of print].
324. Osher Y, Belmaker RH (2009). Omega-3 fatty acids in depression: a review of three studies. *CNS Neuroscience & Therapeutics* 15(2):128-33.

325. Agam G, Bersudsky Y, Berry GT, Moechars D, Lavi-Avnon Y, Belmaker RH (2009). Knockout mice in understanding the mechanism of action of lithium. *Biochemical Society Transactions* 37:1121-1125.
326. Meiri G, Vichovsky Y, Belmaker RH (2009). Omega 3 acid treatment in autism. *Journal of Child and Adolescent Psychopharmacology* 19:449-451.
327. Mann L, Heldman E, Bersudsky Y, Vatner SF, Ishikawa Y, Almog O, Belmaker RH, Agam G (2009). Inhibition of Specific Adenylyl-cyclase Isoforms by Lithium and Carbamazepine but not Valproate may be related to their Antidepressant Effect *Bipolar Disorders* 11:885-96.
328. Shaltiel G, Deutsch J, Rapoport SI, Basselin M, Belmaker RH, Agam G (2009). Is Phosphoadenosinephosphate (PAP) Phosphatase a Target of Lithium's Therapeutic Effect? *Journal of Neural Transmission* 11:1543-1549.
329. Lichtenberg P, Belmaker RH (2010). Subtyping Major Depression. *Psychotherapy and Psychosomatics* 79:131-135 (editorial).
330. Mariotti V, Melissari E, Amar S, Conte A, Belmaker RH, Agam G, Pellegrini S (2010). Effect of prolonged phenytoin administration on rat brain gene expression assessed by DNA microarrays. *Experimental Biology and Medicine* 235:300-310.
331. Osher Y, Bersudsky Y, Belmaker RH (2010). The new lithium clinic. *Neuropsychobiology* 62:17-26.
332. Shlafman N, Shaldubina S, Applebaum J, Belmaker RH, Levine J (2010). No gross abnormality of plasma homocysteine after acute methionine loading in Clinically Stabilized Patients with Schizophrenia. *Asian Journal of Psychiatry* 3:64-66.
333. Bersudsky Y, Applebaum J, Gaiduk Y, Sharony L, Mishory A, Podberezsky A, Agam G, Belmaker RH (2010). Valnoctamide as a valproate substitute with low teratogenic potential in mania: double-blind controlled clinical trial *Bipolar Disorders* 12:376-382.
334. Karyo R, Askira Y, Pinchasov A, Belmaker RH, Agam G, Eldar-Findelman H (2010). Identification of eukaryotic elongation factor-2 as a novel cellular target of lithium and glycogen synthase kinase-3. *Molecular Cellular Neuroscience* 45(4):449-55.
335. Amar S, Ovadia O, Maier W, Ebstein R, Belmaker RH, Mishmar D, Agam G (2010). Copy number variation of the SELENBP1 gene in schizophrenia. *Behavioral and Brain Functions* 6:40.
336. Osher Y, Dobron A, Belmaker RH, Bersudsky Y, Dwolatzky (2011). Computerized testing of neurocognitive function in euthymic bipolar patients compared to those with mild cognitive impairment and cognitively healthy controls. *Psychotherapy and Psychosomatics* 80:298-303.
337. Bromberg A, Levine J, Belmaker RH, Agam G (2011). Hyperhomocysteinemia does not affect global DNA methylation and nicotinamide N-methyltransferase (NNMT) expression in mice. *International Journal of Neuropsychopharmacology* 976-81.

338. Amar S, Belmaker RH, Agam G (2011). The possible involvement of glycogen synthase kinase-3 (GSK-3) in diabetes, cancer and central nervous system diseases. *Current Pharmaceutical Design* 17:2264-77.
339. Bromberg A, Lerer E, Udawela M, Scarr E, Dean B, Belmaker RH, Ebstein R, Agam G (2012). Nicotinamide-n-methyltransferase (NNMT) in schizophrenia: a genetic association and decreased frontal cortex mRNA levels. *International Journal of Neuropsychopharmacology* 15:727-737.
340. Nahman S, Belmaker RH, Azab AN (2012). Effects of lithium on lipopolysaccharide-induced inflammation in rat primary glia cells. *Innate Immun* 18:447-58.
341. Belmaker RH, Bersudsky Y, Agam G (2012). Individual differences and evidence based psychopharmacology. *BMC Medicine*. 7015:10-110.
342. Bloch Y, Applebaum J, Osher Y, Samuel S, Azab A, Agam G, Belmaker RH, Bersudsky Y (2012). Normobaric hyperoxia treatment of schizophrenia. *The Journal of Clinical Psychopharmacology* 32:525-30.
343. Belmaker RH (2012). Successful cultural change: the example of female circumcision among Israeli Bedouin and Israeli Jews from Ethiopia. *Israel Journal of Psychiatry* 49:178-183.
344. Kara NZ, Toker L, Agam G, Anderson GW, Belmaker RH, Einat H (2013). Trehalose induced antidepressant-like effects and autophagy enhancement in mice. *Psychopharmacology* 229(2):367-375.
345. Shtein L, Toker L, Bersudsky Y, Belmaker RH, Agam G (2013). The inositol monophosphatase inhibitor L-690,330 affects pilocarpine-behavior and the forced swim test. *Psychopharmacology* 227(3):503-8.
346. Levi I, Eskira Y, Eisenstein M, Gilon C, Hoffman A, Talgan, Y Fanous J, Bersudsky, Belmaker RH, Agam G, Almog O (2013). The calbindin-D28k binding site on inositol monophosphatase may allow inhibition independent of the lithium site of action, *European Neuropsychopharmacology* 23:1806-1815.
347. Toker L, Kara N, Hadas I, Einat H, Bersudsky Y, Belmaker RH, Agam G (2013). Acute intracerebroventricular inositol does not reverse the effect of chronic lithium treatment in the forced swim test. *Neuropsychobiology* 68:189-192.
348. Sapir R, Zohar A, Berusudsky Y, Belmaker RH, Osher Y (2013). Behavioral addictions in euthymic patients with bipolar I disorder: a comparison to controls. *International Journal of Bipolar Disorders*, 1;27.
349. Toker L, Bersudsky Y, Plaschkes I, Chalifa-Caspi V, Berry G, Moechars D, Belmaker RH, Agam G (2014). Inositol related gene knockouts mimic lithium's effect on mitochondrial function. *Neuropsychopharmacology* 39:319-328.
350. Kara NZ, Karpel O, Toker L, Agam G, Belmaker RH, Einat H (2014). Chronic oral carbamazepine treatment elicits mood-stabilising effects in mice. *Acta Neuropsychiatrica*.

351. Duek O, Osher Y, Belmaker RH, Bersudsky Y, Kofman O (2014). Reward sensitivity and anger in euthymic bipolar disorder. *Psychiatry Research*, 215:95-100.
352. Belmaker RH (2014). Lurasidone and bipolar disorder (editorial). *American Journal of Psychiatry* 171:131-133.
353. Bauer M, Glenn T, Alda M, Andreassen O, Angelopoulos E, Ardu R, Baethge C, Bauer R, Bellivier F, Belmaker RH et al (2014). Relationship between sunlight and the age of onset of bipolar disorder *J Affect Disorder* 167:104-111.
354. Bauer M, Glenn T, Alda M, Andreassen OA, Angelopoulos E, Ardu R, Baethge C, Bauer R, Baune BT, Bellivier F, Belmaker RH, et al (2015). Influence of light exposure during early life on the age of onset of bipolar disorder. *J Psychiatr Res* 64:108.
355. Bauer M, Glenn T, Alda M, Andreassen OA, Angelopoulos E, Ardu R, Baethge C, Bauer R, Bellivier F, Belmaker RH et al (2015). Influence of birth cohort on age of onset cluster analysis in bipolar I disorder. *Eur Psychiatry* 30:99-105.
356. Shtein L, Agam L, Belmaker RH, Bersudsky Y (2015). Inositol deficient food augments a behavioral effect of chronic lithium treatment mediated by inositol monophosphatase inhibition: an animal model with relevance for bipolar disorder. *Journal Of Clinical Psychopharmacology* 35:175-177.
357. Damri O, Sade Y, Toker L, Bersudsky Y, Belmaker RH, Agam G, Azab AN (2015). Molecular effects of lithium are partially mimicked by inositol monophosphatase (IMPA)1 knockout mice in a brain region dependent manner. *European Neuropsychopharmacology* 25:424-434.
358. Azab A.N, Shnaider, Bersudsky Y, Belmaker RH. Lithium Nephrotoxicity. *Int Journal of Bipolar Disorders* (in press).
359. Kara N, Narayanan S, Belmaker, Einat H, Vaidya VA, Agam G (2015). Chronic lithium treatment enhances the number of quiescent neural progenitors but not the number of DCX-positive immature neurons *Int J Neuropsychopharmacol* (ahead of print).
360. Miodovnick C, Bersudsky Y, Syunyakov T, Belmaker RH, Gruzdov J, Shalafman N, Hoffer J, Lerner V. High dose nicotinamide treatment of first episode schizophrenia or schizoaffective disorder increases the skin flush response to nicotinic acid. (submitted).